document incorporate reference part portion registrant proxy statement annual meeting shareholder file day close iii registrant fiscal year proxy statement incorporate reference report reportitem business general segment business geographic area raw material patent trademark seasonality competition environment regulation available information risk factor unresolved staff comment property legal proceeding safety disclosure executive officer registrant market registrant common equity relate stockholder matter issuer purchase equity security select financial datum management discussion analysis result operation financial condition quantitative qualitative disclosure market risk financial statement supplementary data change disagreement accountant account financial disclosure control procedure information iii director executive officer corporate governance executive compensation security ownership certain beneficial owner management relate stockholder matter certain relationship relate transaction director independence principal accountant fee service exhibit financial statement schedule summary signature exhibit index cautionary note forwardlooke statement annual report johnson johnson publicly available document contain forwardlooke statement mean safe harbor provision private security litigation reform act management representatives johnson johnson subsidiaries company time time forwardlooke statement forwardlooke statement relate strictly historical current fact reflect management assumption view plan objective projection future forwardlooke statement identify use word plan expect anticipate estimate word similar meaning conjunction thing discussion future operation expect operating result financial performance impact plan acquisition disposition companys strategy growth product development regulatory approval market position expenditure forwardlooke statement base current belief expectation assumption future event subject uncertainty risk change difficult predict outside company control investor realize underlying assumption prove inaccurate know unknown risk uncertainty materialize company actual result financial condition vary materially expectation projection express imply forwardlooke statement investor caution rely forwardlooke statement risk uncertainty include limited risk relate product development market success competition challenge uncertainty inherent innovation development new improved product technology company continue growth success depend include uncertainty clinical outcome additional analysis exist clinical datum obtain regulatory approval health plan coverage customer access initial continue commercial success challenge company ability obtain protect adequate patent intellectual property right new exist product technologies united states important market impact patent expiration typically follow introduction compete biosimilar generic result revenue market share loss increasingly aggressive frequent challenge company patent competitor seek launch compete generic biosimilar product increase receptivity court united states patent trademark office decision maker challenge potentially result loss market exclusivity rapid decline sale relevant product soon expect competition research development new improved product process technology result product process obsolescence competition reach agreement party collaboration licensing development marketing agreement product technology competition base costeffectiveness product performance technological advance patent attain competitor allegation company product infringe patent intellectual property right party adversely affect company ability sell product question require payment money damage future royalty risk relate product liability litigation regulatory activity product efficacy safety concern base scientific evidence potentially result product withdrawal recall regulatory action united states food drug administration international counterpart decline sale reputational damage increase litigation expense share price impact impact include decline sale reputational damage significant litigation government action adverse company include product liability claim allegation relate pharmaceutical marketing practice contracting strategy impact adverse judgment settlement adequacy reserve relate legal proceeding include patent litigation product liability personal injury claim security class action government investigation employment legal proceeding increase scrutiny health care industry government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty include limited debarment government business failure meet compliance obligation mcneilppc inc consent decree compliance agreement government government agency result significant sanction potential change applicable law regulation affect united states international operation include relate approval new product license patent right sale promotion health care product access reimbursement pricing health care product service environmental protection source raw material compliance local regulation law restrict company ability manufacture sell product relevant market include requirement comply medical device report regulation requirement european union medical device regulation change domestic international tax law regulation include change relate tax cut job act united states federal act tax reform ahv finance switzerland increase audit scrutiny tax authority world exposure additional tax liability potentially excess exist reserve issuance new revise accounting standard financial accounting standard board regulation securities exchange commission risk relate company strategic initiative healthcare market trend pricing pressure result trend health care cost containment include continued consolidation health care provider market participant trend manage care shift government increasingly primary payer health care expense significant new entrant health care market seek reduce cost government pressure company voluntarily reduce cost price increase restrict spend pattern individual institutional governmental purchaser health care product service economic hardship budgetary constraint challenge company ability realize strategy growth include externally source innovation development collaboration strategic acquisition license marketing agreement potential heighten cost external arrangement competitive pressure potential expect strategic benefit opportunity plan complete acquisition divestiture company realize long realize expect potential expect benefit opportunity relate past ongoing restructure action realize long realize expect risk relate economic condition financial market operate internationally impact inflation fluctuation interest rate currency exchange rate potential effect fluctuation revenue expense result margin potential change exportimport trade law regulation policy united states country include increase trade restriction tariff potential drug reimportation legislation impact international operation financial instability international economy sovereign risk possible imposition governmental control restrictive economic policy unstable international government legal system change global climate extreme weather natural disaster affect demand company product service cause disruption manufacture distribution network alter availability good service supply chain affect overall design integrity company product operation impact armed conflict terrorist attack united states part world include social economic disruption instability financial market risk relate supply chain operation difficulty delay manufacture internally party provider supply chain lead voluntary involuntary business interruption shutdown product shortage withdrawal suspension product market potential regulatory action interruption breach company information technology system company vendor result reputational competitive operational business harm financial cost regulatory action reliance global supply chain production distribution process complex subject increase regulatory requirement adversely affect supply source pricing material company product potential expect benefit opportunitie related restructuring action contemplate global supply chain include company transaction jabil realize long realize expect include require approval applicable regulatory authority disruption associate announce global supply chain action adversely affect supply source material company product investor carefully read risk factor describe item annual report description certain risk thing cause company actual result differ materially express forwardlooke statement investor understand possible predict identify factor consider risk describe item complete statement potential risk uncertainty company undertake publicly update forwardlooke statement time time result new information future event developmentspart item business general johnson johnson subsidiaries company approximately employee worldwide engage research development manufacture sale broad range product health care field johnson johnson hold company operate company conduct business virtually country world company primary focus product relate human health wellbee johnson johnson incorporate state new jersey executive committee johnson johnson principal management group responsible strategic operation allocation resource company committee oversee coordinate activity company business segment consumer pharmaceutical medical device strategic parameter provide committee senior management group international operating company responsible strategic plan daytoday operation company subsidiary business segment limited exception manage resident country locate segment business company organize business segment consumer pharmaceutical medical device additional information require item incorporate reference narrative tabular description segment operate result item management discussion analysis result operation financial condition report note segment business geographic area note consolidated financial statement include item report consumer consumer segment include broad range product focus personal healthcare beauty overthe counter pharmaceutical baby care oral care womens health wound care market major brand beauty include aveeno clean clear cilabo neutrogena ogx product line overthecounter medicine include broad family tylenol acetaminophen product sudafe cold flu allergy product benadryl zyrtec allergy product motrin ibuprofen product nicorette smoking cessation product outside zarbees naturals pepcid line acid reflux product baby care include johnson aveeno baby line product oral care include listerine product line major brand women health outside north america stayfree carefree sanitary pad tampon brands wound care brand include bandaid brand adhesive bandage neosporin aid product line product market general public sell online retail outlet distributor world pharmaceutical pharmaceutical segment focus therapeutic area immunology rheumatoid arthritis inflammatory bowel disease psoriasis infectious disease hivaid neuroscience mood disorder neurodegenerative disorder schizophrenia oncology prostate cancer hematologic malignancie cardiovascular metabolism thrombosis diabete pulmonary hypertension pulmonary arterial hypertension medicine segment distribute directly retailer wholesaler hospital health care professional prescription use key product pharmaceutical segment include remicade infliximab treatment number immunemediate inflammatory disease simponi golimumab subcutaneous treatment adult moderate severe rheumatoid arthritis active psoriatic arthritis active ankylose spondylitis moderately active severely active ulcerative colitis simponi aria golimumab intravenous treatment adult moderate severe rheumatoid arthritis active psoriatic arthritis active ankylose spondylitis stelara ustekinumab treatment adult child moderate severe plaque psoriasis adult active psoriatic arthritis adult moderately severely active crohn disease treatment moderately severely active ulcerative colitis tremfya guselkumab treatment adult moderate severe plaque psoriasis edurant rilpivirine prezista darunavir prezcobixrezolsta darunavircobicistat antiretroviral medicine treatment human immunodeficiency virus hiv combination antiretroviral product symtuza darunavircobicistatemtricitabinetenofovir alafenamide oncedaily single tablet regimen treatment hiv concerta methylphenidate hcl extendedrelease tablet cii treatment attention deficit hyperactivity disorder invega sustennaxeplion paliperidone palmitate treatment schizophrenia schizoaffective disorder adult invega trinzatrevicta paliperidone palmitate treatment schizophrenia patient adequately treat invega sustenna month risperdal consta risperidone longacte injection treatment schizophrenia themaintenance treatment bipolar disorder adult zytiga abiraterone acetate treatment metastatic castration resistant prostate cancer crpc metastatic highrisk castrationsensitive prostate cancer imbruvica ibrutinib treatment certain bcell malignancy blood cancer chronic graft versus host disease waldenstrm macroglobulinemia darzalex daratumumab treatment relapsedrefractory multiple myeloma velcade bortezomib treatment multiple myeloma mantle cell lymphoma procriteprex epoetin alfa treatment chemotherapyinduce anemia patient chronic kidney disease xarelto rivaroxaban oral anticoagulant prevention deep vein thrombosis dvt lead pulmonary embolism patient undergo hip knee replacement surgery reduce risk stroke systemic embolism patient nonvalvular atrial fibrillation treatment reduction risk recurrence dvt invokana canagliflozin treatment adult type diabete invokametvokanamet canagliflozinmetformin hcl combination therapy fix dose canagliflozin metformin hydrochloride treatment adult type diabete invokamet canagliflozinmetformin hydrochloride extendedrelease oncedaily fixeddose combination therapy canagliflozin metformin hydrochloride extendedrelease treatment adult type diabete opsumit macitentan monotherapy combination indicate longterm treatment pulmonary arterial hypertension pah uptravi selexipag approve oral selective receptor agonist target prostacyclin pathway pah medicine develop collaboration strategic partner license company maintain active lifecycle development program medical device medical device segment include broad range product orthopaedic surgery interventional solution cardiovascular neurovascular eye health field product distribute wholesaler hospital retailer principally professional field physician nurse hospital eye care professional clinic include orthopaedic product general surgery biosurgical endomechanical energy product electrophysiology product treat cardiovascular disease vision product disposable contact lense ophthalmic product relate cataract laser refractive surgery geographic area johnson johnson subsidiaries company approximately employee worldwide engage research development manufacture sale broad range product health care field company conduct business virtually country world primary focus product relate human health wellbeing product sell international business include describe segment business consumer pharmaceutical medical device principal market product method distribution international business vary country culture product sell international business include develop subsidiary abroad investment activity country outside subject high risk comparable activity investment commercial climate influence financial instability international economy restrictive economic policy political legal system uncertaintie raw material raw material essential company business generally readily available multiple source exception temporary unavailability raw material likely material adverse effect financial result company patent company subsidiary practice obtain patent protection product process possible license significant number patent country relate product product use formulation manufacturing process aggregate believe material importance company operation business company subsidiary face patent challenge party include challenge seek manufacture market generic biosimilar version company key pharmaceutical product prior expiration applicable patent cover product significant legal proceeding claim involve company patent intellectual property describe note legal proceeding intellectual property note consolidated financial statement include item report sale company large product stelara ustekinumab account approximately company total revenue fiscal accordingly patent relate product believe material thecompany set grant patent relate specifically stelara set patent own janssen biotech inc whollyowne subsidiary johnson johnson patent force country outside latest project expiration date patent set patent term extension adjustment europe late project expiration date patent set supplementary protection certificate patent term extension country latest project expiration date addition compete immunology market stelara company currently market simponi golimumab simponi aria golimumab generation immunology product patent relate product force latest project expiration date patent term extension adjustment company market remicade infliximab immunology market company large product patent product expire food drug administration approve infliximab biosimilar sale number product launch extensive description legal matter patent relate remicade note legal proceeding intellectual property pharmaceutical remicade relate case note consolidated financial statement include item report trademark company subsidiary practice sell product trademark obtain protection trademark available mean trademark protect registration country product market company consider trademark aggregate material importance operation business seasonality worldwide sale reflect significant degree seasonality spend heavy fourth quarter year quarter reflect increase spending decision principally advertise research development activity competition product line company subsidiary compete company locally globally competition exist product line regard number size compete company involve competition research internally externally source involve development improvement new exist product process particularly significant development new innovative product protect underlie intellectual property company product portfolio important company success area business competitive environment require substantial investment continue research addition development maintenance customer demand company consumer product involve significant expenditure advertising promotion environment company subject variety international environmental protection measure company believe operation comply material respect applicable environmental law regulation companys compliance requirement change past year expect material effect capital expenditure cash flow earning competitive position regulation company business subject vary degree governmental regulation country operation conduct general trend increasingly stringent regulation enforcement subject costly complex foreign law governmental regulation adverse regulatory action materially adversely affect financial condition business operation drug device cosmetic industry long subject regulation federal state agency primarily product safety efficacy manufacturing advertising labeling safety report exercise broad regulatory power food drug administration fda continue result increase amount test documentation require fda approval new drug device correspond increase expense product introduction similar trend evident major market outside new medical device regulatory framework new privacy regulation europe country example increase regulation regulatory agency purview company operate administrative power subject action product withdrawal recall seizure product civil criminal sanction case thecompany subsidiary deem advisable initiate product recall fda regulatory agency globe increase enforcement activity fda conclude compliance applicable law regulation drug medical device ineffective pose unreasonable health risk fda ban product detain seize adulterate misbrande product order recall repair replacement refund product refuse grant pende application marketing authorization require certificate foreign government export andor require notify health professional product present unreasonable risk substantial harm public health fda assess civil criminal penalty officer employee impose operating restriction companywide basis enjoin andor restrain certain conduct result violation applicable law fda recommend prosecution department justice adverse regulatory action depend magnitude restrict effectively market selling product limit ability obtain future clearance approval result substantial modification business practice operation equivalent enforcement mechanism exist different country conduct business cost human health care continue subject study investigation regulation governmental agency legislative body world attention focus state regulatory agency congress drug price profit program encourage doctor write prescription particular drug recommend use purchase particular medical device increase focus interaction healthcare company health care provider transparency law regulation require disclosure financial relationship company health care provider payer potent force market place increase attention pay drug medical device price appropriate drug medical device utilization quality cost health care generally government agency continue effort repeal modify provision patient protection affordable care act aca pass example federal legislation repeal acas individual mandate tax penalty tax generous employersponsored healthcare plan cms begin permit state impose work requirement person cover medicaid expansion plan certain federal subsidy insurer end certain shortterm insurance plan offer array aca benefit allow extend duration change challenge court longterm impact remain uncertain government continue propose implement change medicare benefit include size manufacturer discount coverage gap catastrophic phase benefit change federal landscape positive negative impact healthcare industry remain uncertain provision federal law potential modification repeal law ultimately affect industry addition business practice health care industry come increase scrutiny particularly government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty company rely global supply chain production distribution process complex subject increase regulatory requirement face unexpected change result brexit affect source supply pricing material company product process subject complex lengthy regulatory approval available information company main corporate website address wwwjnjcom company sec filing available company website wwwinvestorjnjcomseccfm soon reasonably practicable electronically file furnish sec sec filing available secs website wwwsecgov investor public note company announce information wwwfactsaboutourprescriptionopioidscom wwwfactsabouttalccom use website communicate investor public product litigation matter possible information post website deem material information encourage investor interested company review information post website conjunction wwwjnjcom filings press release public conference call webcast addition restate certificate incorporation bylaw write charter audit committee compensation benefit committee nominate corporate governance committee regulatory compliance committee science technology sustainability committee board director company principle corporate governance code business conduct employee code business conduct ethic member board director executive officer corporate governance material available atwwwinvestorjnjcomgovcfm company website provide charge shareholder submit write request provide information wwwjnjcom wwwfactsaboutourprescriptionopioidscom wwwfactsabouttalccom deem report incorporate filing company make sec item risk factor company face number uncertainty risk difficult predict outside company control addition information report company filing sec investor consider carefully factor set forth investor aware possible predict identify factor follow mean complete discussion potential risk uncertainty know unknown risk uncertainty materialize company business result operation financial condition adversely affect potentially material way global sale company pharmaceutical medical device segment negatively impact healthcare reform increase pricing pressure sale companys pharmaceutical medical device product significantly affect reimbursement thirdparty payer government healthcare program private insurance plan manage care organization effort contain healthcare cost payer put downward pressure price product reimburse increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary continued consolidation health care provider result pricing pressure addition increase political scrutiny result additional pricing pressure outside numerous major market include japan pervasive government involvement funding healthcare regard directly indirectly impose price control limit access reimbursement company product reduce value intellectual property protection company subject significant legal proceeding result significant expense fine reputational damage ordinary course business johnson johnson subsidiary subject numerous claim lawsuit involve issue patent dispute product liability claim product sale marketing pricing practice violate antitrust unfair trade practice andor consumer protection law significant proceeding describe note legal proceeding note consolidated financial statement include item report litigation general security derivative action class action multidistrict litigation particular expensive disruptive matter include thousand plaintiff determine class action involve party seek large andor indeterminate amount include punitive exemplary damage remain unresolved year example company defendant numerous lawsuit arise use body powder contain talc primarily johnson baby powder company sale manufacturing marketing opioidswhile company believe substantial defense matter feasible predict ultimate outcome litigation company future require pay significant amount result settlement judgment matter potentially excess accrual include matter company hold jointly severally liable defendant resolution increase accrual matter report period material adverse effect company result operation cash flow period furthermore result cost availability factor effective november company cease purchase thirdparty product liability insurance product reliability safety effectiveness concern significant negative impact sale result operation lead litigation cause reputational damage concern product safety raise internally litigant regulator consumer advocate base scientific evidence result safety alert product recall governmental investigation regulatory action fda counterpart country private claim lawsuit payment fine settlement decline sale reputational damage circumstance result damage brand image brand equity consumer trust company product product recall past future prompt government investigation inspection shutdown manufacture facility continue product shortage relate sale decline significant remediation cost reputational damage possible civil penalty criminal prosecution change tax law exposure additional tax liability negatively impact company operating result change tax law regulation world negatively impact company effective tax rate result operation change statutory tax rate country result revaluation company defer tax asset liability relate particular jurisdiction period new tax law enact change result expense benefit record company consolidate statement earning company closely monitor proposal arise country operate change statutory tax rate occur time related expense benefit record material fiscal quarter year law change enactedin fiscal year switzerland enact federal act tax reform ahv financing traf effective january december certain canton company operate enact portion tax reform stipulate swiss federal law enactment future possible guidance applicable tax authority material impact company operating result note income taxis additional information company conduct business file tax return numerous country address tax audits dispute tax authority connection organization economic cooperation development base erosion profit shift bep project company require disclose information tax authority operation world lead great audit scrutiny profit earn country company regularly assess likely outcome tax audits dispute determine appropriateness tax reserve tax authority position tax treatment contrary company expectation result tax liability excess reserve company able successfully secure defend intellectual property right essential company business company own license significant number patent proprietary right determine patent office court lawmaker country relate product manufacturing process right essential company business materially important company result operation public policy outside increasingly unfavorable intellectual property right company certain obtain adequate patent protection new product technologie important market protection grant long originally anticipate competitor routinely challenge validity extent company own licensed patent proprietary right litigation interference opposition proceeding proceeding absorb resource protract unpredictable addition challenge company product infringe patent party result need pay past damage future royalty adversely affect competitive position sale product question company face increase patent challenge party seek manufacture market generic biosimilar version company key pharmaceutical product prior expiration applicable patent cover product manufacturer generic version innovative human pharmaceutical product challenge validity claim noninfringement innovator product abbreviate new drug application anda process fda biologics price competition innovation act bpcia enact create new regulatory pathway approval fda biosimilar alternative innovatordevelope biological product create mechanism biosimilar applicant challenge patent innovator biologics inter part review ipr process uspto created america invents act competitor challenge patent hold company subsidiary event company successful defend patent challenge atrisk launch despite pende patent infringement litigation generic biosimilar firm product company lose major portion revenue reference product short period time current legal proceeding involve company patent intellectual property right describe note legal proceedingsintellectual property note consolidated financial statement include item report company business operate highly competitive product market competitive pressure adversely affect company earning company face substantial competition operate segment geographic market company business compete company size basis costeffectiveness technological innovation intellectual property right product performance real perceive product advantage price availability rate reimbursement company compete market participant secure right acquisition collaboration license agreement party competition right product candidate technology result significant investment acquisition cost onerous agreement term company competitor development effective costly product andor ability secure patent intellectual property right successfully market product ahead company negatively impact sale company exist product ability bring new product market despite significant prior investment relate product developmentfor company pharmaceutical business loss patent exclusivity product follow substantial reduction sale competitor gain regulatory approval generic compete product enter market similar competition trigger loss exclusivity biological product company medical device business technological innovation product quality reputation customer service especially important competitiveness development company new improved product process technology threaten company product technology desirable economical obsolete company consumer business face intense competition brand product retailer privatelabel brand company fail sufficiently differentiate market brand consumer product adversely affect revenue profitability product significant challenge delay company innovation development new product technology indication adverse impact company longterm success company continue growth success depend ability innovate develop new differentiate product service address evolve health care need patient provider consumer development successful product technology necessary offset revenue loss company exist product lose market share factor competition loss patent exclusivity new product introduce past year account approximately sale company certain able develop license acquire company product technology particular product candidate grant regulatory approval approve product commercially successful company pursue product development internal research development collaboration acquisition joint venture license arrangement party context develop new product particularly pharmaceutical biotechnology product medical device require significant investment resource year biopharmaceutical research development program result commercially viable product process depend factor include ability discern patient health care provider future need develop promise new compound strategy technology achieve successful clinical trial result secure effective intellectual property protection obtain regulatory approval timely basis reach market successfully differentiate company product compete product approach treatment new product enhancement exist product accept quickly significantly marketplace product price competition change customer preference healthcare purchasing pattern resistance healthcare provider uncertainty thirdparty reimbursement follow initial regulatory approval success product adversely impact safety efficacy finding large real world patient population market entry competitive product company face increase regulatory scrutiny impose significant compliance cost expose company government investigation legal action penalty like company healthcare industry company subject extensive regulation investigation legal action national state local government agency country operate regulatory issue compliance good manufacturing practice cgmp comparable quality regulation foreign country manufacturer drug device consumer product lead fine penalty product recall product shortage interruption production delay new product approval litigation addition marketing pricing sale company product subject regulation investigation legal action include federal food drug cosmetic act medicaid rebate program federal state false claim act state unfair trade practice act consumer protection law increase scrutiny health care industry business practice recent year government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty include limited debarment participation government healthcare program debarment material adverse effect company business result operation significant current investigation litigation bring government agency describe note legal proceedingsgovernment proceeding note consolidated financial statement include item report company face variety risk associate conduct business internationally company extensive operation business activity outside accompany certain financial economic political risk include list foreign currency exchange fiscal approximately company sale occur outside approximately europe western hemisphere exclude asiapacific africa region change nonus currency relative dollar impact company revenue expense thecompany use financial instrument mitigate impact fluctuation currency exchange rate cash flow unhedged exposure continue subject currency fluctuation addition weaken strengthen dollar result significant favorable unfavorable translation effect operating result company nonus business activity translate dollar inflation currency devaluation risk company face challenge maintain profitability operation economy experience high inflation rate company account operation argentina begin fiscal quarter venezuela highly inflationary prior threeyear cumulative inflation rate surpass company strive maintain profit margin area cost reduction program productivity improvement periodic price increase experience operating loss result continued inflation addition impact currency devaluation country experience high inflation rate significant currency exchange fluctuation negatively impact company operate result illegal importation pharmaceutical product illegal importation pharmaceutical product country government price control market dynamic result low price adversely affect company sale profitability country company operate exception limited quantity prescription drug personal use foreign import pharmaceutical product illegal current law volume illegal import continue rise ability patient customer obtain lowerprice import grow significantly antibribery regulation company subject federal foreign law govern international business practice respect payment government official law include foreign corrupt practice act fcpa prohibit publicly trade company promise offering give value foreign official corrupt intent influence foreign official purpose help company obtain retain business gain improper advantage company business heavily regulate involve significant interaction foreign official country outside health care provider prescribe human pharmaceutical employ government purchaser human pharmaceutical government entity company interaction prescriber purchaser subject regulation fcpa addition application enforcement fcpa jurisdiction company operate law regulation include bribery act aim prevent penalize corrupt anticompetitive behavior enforcement activity law subject company additional administrative legal proceeding action include claim civil penalty criminal sanction administrative remedy include exclusion health care program legal social political risk risk inherent conduct business globally include protective economic policy take government trade protection measure importexport licensing requirement compliance local regulation law include country regulatory requirement restrict company ability manufacture sell product relevant market diminish protection intellectual property contractual right certain jurisdiction potential nationalization expropriation company foreign asset disruption market war armed conflict terrorism social upheaval pandemic interruption delay manufacture operation adversely affect company business sale reputation company manufacture product require timely delivery sufficient amount complex highquality component material company subsidiary operate manufacturing facility source hundred supplier world company past future face unanticipated interruption delay manufacture internal external supply chain manufacturing disruption occur reason include regulatory action production quality deviation safety issue labor dispute sitespecific incident fire natural disaster hurricane severe weather event raw material shortage political unrest terrorist attack delay difficulty manufacturing result product shortage decline sale reputational impact significant remediation relate cost associate address shortage company rely party manufacture certain product failure loss party manufacturer result delay increase cost adversely affect business company rely party manufacture certain product depend party manufacturer allocate portion manufacturing capacity sufficient meet need produce product acceptable qualityand acceptable manufacturing yield deliver product timely basis acceptable price guarantee party manufacturer able meet nearterm longterm manufacturing requirement result lose sale adverse effect business risk associate reliance party manufacture product include reliance party regulatory compliance quality assurance misappropriation company intellectual property limit ability manage inventory possible breach manufacturing agreement party possible termination nonrenewal manufacturing agreement party time costly inconvenient party manufacturer suffer damage facility lose benefit material agreement experience power outage encounter financial difficulty unable secure necessary raw material supplier suffer reduction efficiency company experience significant business disruption event disruption company need seek source qualified party manufacturer likely result delay increase cost affect business adversely counterfeit version product harm patient negative impact revenue earning reputation business industry continues challenge vulnerability distribution channel illegal counterfeiting presence counterfeit product grow number market internet party illegally distribute sell counterfeit version product meet rigorous manufacturing testing standard distributor patient counterfeit product visually indistinguishable authentic version counterfeit medicine pose risk patient health safety condition manufacturedoften unregulated unlicensed uninspected unsanitary sitesa lack regulation content industry failure mitigate threat counterfeit medicine adversely impact business reputation impact patient confidence authentic product potentially result lose sale product recall increase threat litigation addition diversion product authorize market channel result reduced revenue negatively affect profitability information security incident include cybersecurity breach negative impact company business reputation meet business objective company rely internal information technology system network party vendor process store sensitive datum include confidential research business plan financial information intellectual property personal datum subject legal protection extensive information security cybersecurity threat affect company globally pose risk security availability system network confidentiality integrity availability company sensitive datum company continually assess threat make investment increase internal protection detection response capability ensure company party provider require capability control address risk date company experience material impact business operation result information cybersecurity attack frequently change attack technique increase volume sophistication attack potential company adversely impact impact result reputational competitive operational business harm financial cost regulatory action company maintain cybersecurity insurance event information security cyber incident coverage sufficient cover financial loss item unresolved staff comment applicable item property company subsidiary operate manufacturing facility occupy approximately million square foot floor space manufacturing facility industry segment company business approximately follow square foot segment thousand consumer pharmaceutical medical device worldwide total facility consumer segment pharmaceutical segment medical device segment outside facility consumer segment pharmaceutical segment medical device segment location manufacture facility major geographic area world follow number square feet geographic area facility thousands united states europe western hemisphere exclude africa asia pacific worldwide total addition manufacture facility discuss company maintain numerous office warehouse facility world research facility discuss item management discussion analysis result operation financial condition report company subsidiary generally seek lease manufacturing facility principally nonus location lease office warehouse facility lease company engage contract manufacturer company commit maintain property good operating condition mcneilppc inc johnson johnson consumer inc mcneilppc continue operate consent decree sign fda govern certain mcneil consumer healthcare manufacturing operation require mcneilppc remediate facility operate lancaster pennsylvania fort washington pennsylvania las piedras puerto rico consent decree follow fda inspection mcneilppc receive notification fda manufacture facility conformity applicable law regulation commercial production restart consent decree receiving notice fda compliance applicable law regulation facility subject fiveyear audit period thirdparty cgmp expert thirdparty expert continue reassess site time information lease obligation note lease commitment note consolidated financial statement include item report segment information addition property plant equipment contain note segment business geographic area note consolidated financial statement include item reportitem legal proceeding information call item incorporate reference information set forth note legal proceeding note consolidated financial statement include item report addition johnson johnson subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund comparable state local foreign law primary relief seek cost past andor future remediation item safety disclosure applicable executive officer registrant list executive officer company family relationship executive officer arrangement understand executive officer person pursuant executive officer select annual meeting board director executive officer elect board hold office year respective successor elect qualified early resignation removal information regard director company include information alex gorsky executive officer incorporate reference material caption item election director proxy statement age position joaquin duato vice chairman executive committeea peter fasolo phd member executive committee executive vice president chief human resource officerb alex gorsky chairman board directors chairman executive committee chief executive officer ashley mcevoy member executive committee executive vice president worldwide chairman medical devicesc thibaut mongon member executive committee executive vice president worldwide chairman consumerd michael sneed member executive committee executive vice president global corporate affair chief communication officere paulus stoffel vice chairman executive committee chief scientific officerf jennifer taubert member executive committee executive vice president worldwide chairman pharmaceuticalsg michael ullmann member executive committee executive vice president general counselh kathryn wengel member executive committee executive vice president chief global supply chain officeri joseph wolk member executive committee executive vice president chief financial officerj duato join company janssenfarmaceutica spain subsidiary company hold executive position increase responsibility pharmaceutical sector name company group chairman pharmaceutical name worldwide chairman pharmaceutical duato member executive committee name executive vice president worldwide chairman pharmaceuticals july duato promote vice chairman executive committee responsibility company pharmaceutical consumer sector supply chain information technology global service health wellness groupsb fasolo join company vice president worldwide human resource cordis corporation subsidiary company subsequently name vice president global talent management company leave johnson johnson join kohlberg kravis roberts chief talent officer fasolo return company vice president global human resource member executive committee april name executive vice president chief human resource officer fasolo responsibility global talent recruiting diversity compensation benefit employee relation aspect human resource agenda company mcevoy join company assistant brand manager mcneil consumer health subsidiary company advance position increase responsibility appoint company group chairman vision care follow company group chairman consumer medical device july mcevoy promote executive vice president worldwide chairman medical device member executive committee mcevoy responsibility surgery orthopaedic interventional solution eye health business ethicon depuy synthe biosense webster johnson johnson vision mongon join company director marketing vision care group france subsequently hold general management position country manager france belgium north africa managing director latin america president asiapacific mongon transition pharmaceutical sector global commercial strategy leader neuroscience therapeutic area join consumer sector company group chairman asiapacific promote executive vice president worldwide chairman consumer member executive committee mongon responsibility global development johnson johnsons health wellness product solution beauty otc oral care baby care womens health wound care sneed join company marketing assistant personal product company subsidiary company gain increase responsibility executive position global enterprise sneed appoint company group chairman consumer north america follow company group chairman vision care franchise vice president global corporate affair chief communication officer sneed appoint executive vice president global corporate affair chief communication officer january member executive committee july lead company global marketing communication design philanthropy function stoffels rejoin company acquisition tibotec virco chief executive officer virco chairman tibotec appoint company group chairman global virology assume role company group chairman pharmaceuticals stoffels appoint global head research development pharmaceutical worldwide chairman pharmaceutical stoffels appoint chief scientific officer member executive committee stoffel name executive vice president chief scientific officer stoffels promote vice chairman executive committee chief scientific officer responsible company innovation agenda pharmaceutical medical device consumer sector product safety strategy company global public health strategy taubert join company worldwide vice president johnson johnson pharmaceutical services subsidiary company hold executive position increase responsibility pharmaceutical sector appoint company group chairman north america pharmaceutical company group chairman americas pharmaceuticals july taubert promote executive vice president worldwide chairman pharmaceutical member executive committee taubert responsibility immunology infectious disease neuroscience oncology cardiovascular metabolism pulmonary hypertension business janssen ullmann join company corporate attorney law department appoint corporate secretary serve role time hold management position law department name general counsel medical device diagnostic appoint vice president general counsel member executive committee april ullmann name executive vice president general counsel ullmann worldwide responsibility legal government affair policy global security aviation health care compliance privacy wengel join company project engineer engineering supervisor janssen subsidiary company tenure company hold variety strategic leadership executive position global enterprise role operation quality engineer new product information technology technical business function wengel chief quality officer company promote vice president johnson johnson supply chain july promote executive vice president chief global supply chain officer member executivecommittee wolk join company finance manager business development orthomcneil subsidiary company year hold variety senior leadership role segment function company subsidiary pharmaceutical medical device supply chain serve vice president finance chief financial officer janssen pharmaceutical companies johnson johnson wolk vice president investor relation july appoint executive vice president chief financial officer member executive committee wolk play strategic role overall management company lead development execution company global longterm financial strategy item market registrant common equity relate stockholder matter issuer purchase equity security february record holder common stock company additional information call item incorporate reference follow section report note common stock stock option plan stock compensation agreement note consolidated financial statement include item item security ownership certain beneficial owner management relate stockholder matter equity compensation plan information issuer purchase equity security december company announce board director approve share repurchase program authorize company purchase billion company common stock share repurchase place time time open market privately negotiate transaction repurchase program complete fiscal quarter follow table provide information respect common stock purchase company fiscal fourth quarter common stock purchase open market systematic plan meet need company compensation program repurchase include stockforstock option exercise settle fiscal fourth quarter total number maximum number share unit approximate dollar purchase value share total number publicly unit share avg price announce plan purchase fiscal period purchase pay share program plan program september october october november november december total fiscal fourth quarter company repurchase aggregate share johnson johnson common stock openmarket transaction share purchase openmarket transaction systematic plan meet need company compensation program september share repurchase program complete aggregate share purchase total billion inception repurchase program announce december item select financial datum summary operation statistical data dollar million share amount sale customer sale customer international total sale cost product sell sell marketing administrative expense research development expense inprocess research development interest income interest expense net portion capitalize income expense net restructure earning provision taxis income provision taxis income net earning add net loss attributable noncontrolle interest net earning attributable johnson johnson percent sale customer dilute net earning share common stock percent return average shareholder equity percent increase decrease previous year sale customer dilute net earning share supplementary balance sheet datum property plant equipment net addition property plant equipment total asset longterm debt operate cash flow common stock information dividend pay share shareholder equity share market price share yearend close average share outstanding million basic diluted employee thousand attributable johnson johnson meaningful item management discussion analysis result operation financial condition organization business segment description company business segment johnson johnson subsidiaries company approximately employee worldwide engage research development manufacture sale broad range product health care field company conduct business virtually country world primary focus product relate human health wellbee company organize business segment consumer pharmaceutical medical device consumer segment include broad range product baby care oral care beauty overthecounter pharmaceutical womens health wound care market product market general public sell retail outlet distributor world pharmaceutical segment focus therapeutic area include immunology infectious disease neuroscience oncology pulmonary hypertension cardiovascular metabolic disease product segment distribute directly retailer wholesaler hospital health care professional prescription use medical device segment include broad range product orthopaedic surgery interventional solution cardiovascular neurovascular eye health field product distribute wholesaler hospital retailer principally professional field physician nurse hospitals eye care professional clinic executive committee johnson johnson principal management group responsible strategic operation allocation resource company committee oversee coordinate activitie consumer pharmaceutical medical device business segment product line company compete company locally globally world competition exist product line regard number size compete company involve competition research involve development improvement new exist product process particularly significant development new innovative product protect underlie intellectual property company product portfolio important company success area business competitive environment require substantial investment continue research addition development maintenance customer demand company consumer product involve significant expenditure advertising promotion management objectives credo foundation company purpose blend heart science ingenuity profoundly change trajectory health humanity company commit bring breadth depth ensure health people today future generation unite common ambition company poise fulfill purpose successfully meet demand rapidly evolve market compete company broadly base human healthcare commit create value develop accessible high quality innovative product service new product introduce past year account approximately sale billion invest research development billion spend acquisition reflect management commitment create lifeenhancing innovation create value partnership profoundly change trajectory health humanity critical driver company success diverse employee worldwide employee empower inspire lead company credo purpose guide allow employee use company reach size advance company purpose lead agility urgency leverage extensive resource enterprise enable company innovate execute excellence ensure company remain focused address unmet need society day invest endure impact ultimately deliver value patient consumer healthcare professional employee communitie shareholder chartaabbajpg chartfebddaeadjpgresult operation analysis consolidate sale discussion result operation financial condition pertain fiscal year company annual report fiscal year end december item management discussion analysis result operation financial condition worldwide sale increase billion compare increase sale change consist follow sale increasedecrease volume price currency total net impact acquisition divestiture worldwide sale growth negative impact positive impact sale company billion billion represent increase sale international company billion billion represents increase fiveyear compound annual growth rate worldwide international sale respectively tenyear compound annual growth rate worldwide international sale respectively sale company europe experience sale decline compare prior year include operational growth offset negative currency impact sale company western hemisphere exclude experienced sale decline compare prior year include operational growth offset negative currency impact sale company asiapacific africa region achieve growth compare prior year include operational growth partially offset negative currency impact company utilize wholesaler distribute product segment represent approximately total consolidated revenue company wholesaler distribute product segment represent approximately total consolidated revenue chartaccadacacjpganalysis sale business segment consumer segment consumer segment sale billion increase include operational growth negative currency impact consumer segment sale billion increase international sale billion decrease include operational growth negative currency impact acquisition divestiture net positive impact operational sale growth worldwide consumer segment major consumer franchise sale change dollar million beauty otc baby care oral care womens health wound careother total consumer sale beauty franchise sale billion increase compare prior year growth primarily drive incremental sale acquisition ciz holdings ltd drcilabo japan market growth share gain neutrogena aveeno product growth partially offset divestiture roc nizoral fiscal year overthecounter otc franchise sale billion increase compare prior year growth primarily drive incremental sale acquisition zarbeesadditional contributor growthwere tylenol child motrin digestive health product antismoke aids baby care franchise sale billion decrease compare prior year primarily johnson competitive pressure couple comparison prior year relaunch activity baby center divestiture oral care franchise sale billion decrease compare prior year growth listerine mouthwash ready tab outside offset share decline retailer destocke negative impact currency women health franchise sale billion decrease compare prior year decline primarily drive negative impact currency weakness liner partially offset strength napkins asia pacific latin america wound careother franchise sale billion decrease compare prior year decline primarily drive divestiture compee outside negative impact currency pharmaceutical segment pharmaceutical segment sale billion increase include operational growth negative currency impact sale billion increase international sale billion increase include operational growth negative currency impact net impact acquisition divestiture pharmaceutical segment operational sale growth negligible adjustment previous reserve estimate compare prior year positively impact pharmaceutical segment operational growth approximately primarily immunology cardiovascularmetabolismother therapeutic area major pharmaceutical therapeutic area sale change dollar million total immunology remicade simponisimponi aria stelara tremfya immunology total infectious disease edurantrilpivirine prezista prezcobixrezolstasymtuza infectious disease total neuroscience concertamethylphenidate invega sustennaxeplioninvega trinzatrevicta risperdal consta neuroscience total oncology darzalex imbruvica velcade zytiga abiraterone acetate oncology total pulmonary hypertension opsumit tracleer bosentan uptravi pulmonary hypertension total cardiovascular metabolism xarelto invokana invokamet procriteprex total pharmaceutical sale immunology product sale billion represent increase compare prior year growth drive strong uptake stelara ustekinumab crohn disease tremfya guselkumab psoriasis expand indication simponisimponi aria golimumab immunology market growth immunology negatively impact low sale remicade infliximab increase discountsrebate biosimilar competition patent remicade infliximabin certain country europe expire february biosimilar version remicade introduce certain market outside result reduction sale remicade market additional biosimilar competition likely result reduction remicade sale market outside united states biosimilar version remicade introduce additional competitor continue enter market continue infliximab biosimilar competition market result reduction sale remicade note consolidated financial statement description legal matter remicade patent infectious disease product sale billion represent increase compare prior year strong sale symtuza andthe launch juluca dolutegravirrilpivirine partially offset low sale prezista prezcobixrezolsta darunavircobicistat increase competition loss exclusivity prezista certain country outside neuroscience product sale billion represent increase compare prior year strong sale longacte injectable invega trinzatrevictapaliperidone palmitate invega sustennaxeplion partially offset cannibalization risperdal consta risperidone oncology product achieve sale billion represent increase compare prior year contributor growth strong sale darzalex daratumumab continue market growth share gain imbruvica ibrutinib increase patient uptake globally additionally sale launch erleada apalutamide contribute growth growth negatively impact decline sale zytiga abiraterone acetate drive generic competition partially offset increase sale outside low sale velcade bortezomib generic competition pulmonary hypertension product achieve sale billion represent increase compare prior year sale opsumit macitentan uptravi selexipag continued market growth increase share gain sale tracleer bosentan negatively impact generic cannibalization opsumit cardiovascularmetabolismother product sale billion decline compare prior year xarelto rivaroxaban sale volume growth offset high discount rebate low sale invokanainvokamet canagliflozin share loss competitive pressure safety label update low sale procrit eprex epoetin alfa biosimilar competition company advanced pipeline regulatory submission approval new drug additional indication exist drug follow product chemical indication approval approval filing filing balversa erdafitinib treatment locally advanced metastatic urothelial cancer darzalex daratumumab combination regimen newly diagnose transplanteligible patient multiple myeloma newly diagnose patient multiple myeloma combination lenalidomide dexamethasone splitdosing regimen combination therapy transplant ineligible multiple myeloma patient subcutaneous formulation multiple myeloma erleada apalutamide treatment metastatic castrationsensitive prostate cancer treatment metastatic hormonesensitive prostate cancer expand use combination obinutuzumab adult patient previously untreated chronic imbruvica ibrutinib lymphocytic leukemia combination rituximab waldenstrm macroglobulinemia treatment chronic lymphocytic leukemia combination obinutuzumab invokana canagliflozintreatment diabetic kidney disease rilpivirine cabotegravir monthly injectable drug regimen treatment hiv spravato esketamine treatmentresistant depression rapid reduction depressive symptom adult major depressive disorder active suicidal ideation intent stelara ustekinumab extended use treatment moderately severely active ulcerative colitis treatment pediatric patient moderate severe plaque psoriasis tremfya guselkumab onepress patientcontrolle injector treatment adult active psoriatic arthritis xarelto rivaroxaban prevention blood clot acutely ill medical patient medical device segment medical device segment sale billion decrease include operational decrease negative currency impact sale billion decrease compare prior year international sale billion decrease compare prior year operational decrease negative currency impact net impact acquisition divestiture medical device segment worldwide operational sale growth negative divestiture lifescan advanced sterilization product asp impact approximately respectively major medical device franchise sale change dollar million surgery advanced general specialty orthopaedic hip knee trauma spine vision contact lensesother surgical interventional solution diabetes care total medical device sale lifescan divest fiscal fourth quarter percentage great meaningful surgery franchise sale billion decrease growth advanced surgery primarily drive endocutter biosurgery energy product decline general surgery primarily drive negative impact currency partially offset growth wound closure product decline specialty surgery primarily drive divestiture sterilization business asp partially offset growth aesthetic product orthopaedic franchise sale billion decrease include operational growth offset negative currency impact compare prior year growth hip drive leadership position anterior approach strong market demand actis stem kincise surgical automate system knee grow outside new product couple continued global uptake attune revision offset negative currency impact growth trauma strong market growth couple continue uptake new product decline spine primarily drive base business decline spine partially offset growth sport lead new product monovisc growth asia pacific vision franchise achieve sale billion increase growth primarily drive strength daily disposable lense acuvue oasys contact lense category surgical operational growth primarily drive strength cataract outside partially offset competitive pressure interventional solution franchise achieve sale billion increase strong growth electrophysiology business drive atrial fibrillation procedure growth strong thermocool smarttouch contact force sense catheter diagnostic catheter salesanalysis consolidate earning provision taxis income consolidated earning provision taxis income billion billion fiscal year end respectively percent sale consolidated earning provision taxis income respectively cost product sell sell marketing administrative expense cost product sell sell marketing administrative expense percent sale follow sale cost product sell percent point increasedecrease prior year sell marketing administrative expense percent point increasedecrease prior year cost product sell percent sale increase compare period year ago primarily drive negative impact currency pharmaceutical business increase intangible asset amortization expense intangible asset amortization expense billion include cost product sell compare billion decrease percent sale sell marketing administrative expense compare prior year primarily favorable segment mix high percentage sale come pharmaceutical business plan prioritization reduce brand marketing expense consumer business partially offset increase selling marketing investment medical device business research development expense research development expense segment business follow dollar million sale sale consumer pharmaceutical medical device total research development expense percent increasedecrease prior year percent segment sale research development activity represent significant company business expenditure relate process discover testing develop new product upfront payment developmental milestone improve exist product ensure product efficacy regulatory compliance prior launch company remain committed invest research development aim deliver high quality innovative product worldwide cost research development activity increase compare primarily drive increase investment medical device business relate robotic digital surgery platform high upfront developmental milestone payment primarily argenx collaboration pharmaceutical business research facility locate belgium brazil china france germany india israel netherlands poland singapore sweden switzerland united kingdom additional support country inprocess research development iprd fiscal quarter company record iprd charge billion remain intangible asset value relate development program investigational drug treatment respiratory syncytial virus rsv human metapneumovirus hmpv acquire acquisition alios biopharma inc impairment charge base additional information include clinical datum available lead company decision abandon development fiscal quarter company record impairment charge billion include partial impairment charge billion relate development program impairment charge billion discontinuation development project antithrombin antibody associate acquisition limited income expense net income expense net account company record gain loss relate sale writedown certain investment equity security hold johnson johnson innovation jjdc inc jjdc unrealized gain loss investment gain loss divestiture certain transactional currency gain loss acquisitionrelate cost litigation accrual settlement royalty income change income expense net fiscal year additional net expense billion primarily attributable litigation expense billion primarily relate agreement principle settle opioid litigation billion compare litigation expense billion partially offset divestiture gain billion billion relate divestiture asp business addition fiscal year include high unrealized gain security billion equity stepup gain billion relate company previously hold equity investment cilabo low restructure relate expense billion compare period year ago divestiture gain approximately billion include lifescan business nizoral roc certain nonstrategic pharmaceutical product additionally include reversal contingent liability billion interest income expense fiscal year include net interest income compare expense fiscal year primarily positive effect net investment hedge arrangement certain cross currency swap low average debt balance cash cash equivalent marketable security total billion end average billion compare cash cash equivalent marketable security total billion billion average cash balance total debt balance end billion average debt balance billion compare billion end average debt balance billion decrease debt retirement longterm debt income tax segment income tax segment business follow income tax segment sale percent segment sale dollar million consumer pharmaceutical medical device total net expense allocate segment earning provision taxis income note consolidated financial statement detail amount allocate segment include interest income expense general corporate income expense consumer segment consumer segment income tax percent sale versus decrease income tax percent sale compare primarily attributable high expense litigation billion intangible asset amortization billion restructuring billion fiscal year compare fiscal year partially offset plan prioritization brand marketing expense reduction fiscal year include gain billion relate company previously hold equity investment cilabo divestiture gain fiscal year include gain billion divestiture nizoral pharmaceutical segment pharmaceutical segment income tax percent sale versus decrease income tax percent sale primarily high litigation expense billion primarily agreement principle settle opioid litigation billion increase spending research development include billion upfront payment argenx partially offset billion higher unrealized gain security low inprocess research development charge billion low actelion acquisition integration relate cost compare fiscal year addition fiscal year include contingent liability reversal billion high divestiture gain billion medical device segment medical device segment income tax percent sale versus increase income tax percent sale primarily attributable high divestiture gain divestiture gain fiscal include gain billion relate asp business divestiture gain fiscal year include gain billion relate lifescan additionally fiscal year include low litigation expense billion low restructuring charge billion low intangible asset amortization expense billion compare fiscal year partially offset increase investment robotic digital solution restructure fiscal second quarter company announce plan implement action global supply chain intend enable company focus resource increase investment critical capability technology solution necessary manufacture supply product portfolio future enhance agility drive growth company expect supply chain action include expand use strategic collaboration bolster initiative reduce complexity improve costcompetitiveness enhancing capability optimize network discussion specific future action ongoing subject relevant consultation requirement finalize total company expect action generate approximately billion annual pretax cost saving substantially deliver company expect record pretax restructuring charge approximately billion company estimate approximately cumulative pretax cost result cash outlay company record pretax charge billion include follow line consolidate statement earning billion restructuring billion income expense billion cost product sell total project cost approximately billion record restructure announce note consolidated financial statement additional detail relate restructuring program provision taxis income worldwide effective income tax rate discussion relate fiscal provision taxis refer note consolidated financial statement september swiss parliament approve federal act tax reform ahv financing traf public referendum hold switzerland approve federal reform proposal fiscal quarter swiss federal council enact traf effective january february public referendum legislative change hold remain canton company significant operation legislation approve voter formal enactment expect fiscal half company elect transitional provision canton net financial benefit estimate billion billion fiscal half company believe traf material impact company ongoing consolidated effective tax rate begin fiscal year liquidity capital resource liquidity cash flow cash cash equivalent billion end compare billion end primary source use cash contribute billion decrease approximately billion cash generate operating activity offset billion net cash investing activity billion net cash financing activity addition company billion marketable security end billion end note consolidated financial statement additional detail cash cash equivalent marketable security cash flow operation billion result billion net earning billion noncash expense adjustment depreciation amortization stockbase compensation asset writedown primarily relate alio iprd asset favorable increase account payable accrue liability liabilitie billion reduce billion related increase account receivable inventory current noncurrent asset noncash expense adjustment billion increase defer tax provision net gain sale assetsbusinesse billion primarily related asp divestiture investing activity use billion cash primarily acquisition billion primarily relate acquisition auris health inc cilabo additions property plant equipment billion billion net purchase investment invest activity include source billion proceed disposal assetsbusinesse primarily asp divestiture proceed credit support agreement billion financing activity use billion cash primarily dividend shareholder billion repurchase common stock billion net retirement short long term debt billion financing activity include source billion proceed stock option exercisedemployee withholding tax stock award financing activity december company announce board director approve share repurchase program authorize company purchase billion company share common stock share acquire available general corporate purpose company finance share repurchase program available cash september billion repurchase program program complete december company note payable longterm debt excess cash cash equivalent marketable security december net debt position billion compare prior year billion decrease net debt position retirement debt debt balance end billion compare billion company continue access liquidity commercial paper market additionally result tcja company access cash outside significantly reduce cost company anticipate operate cash flow ability raise fund external source borrowing capacity exist committed credit facility access commercial paper market continue provide sufficient resource fund operating need include agreement principle settle opioid litigation potentially pay year discuss note consolidated financial statement internal revenue service irs complete audit tax year currently audit tax year company currently expect completion audit settlement relate tax liability fiscal year december company classify unrecognized tax benefit relate interest approximately billion current liability accrue taxis income line consolidate balance sheet expect pay month respect irs audit subsequent december company payment approximately billion treasury relate estimate tax audit liability anticipation final settlement later fiscal completion tax audit result additional adjustment company unrecognized tax benefit liability material impact company future operating result cash flow period audit substantially complete company monitor global capital market ongoing basis time time raise capital market condition favorable company file shelf registration february enable issue debt security timely basis update require additional detail borrowing note consolidated financial statement finance market risk company use financial instrument manage impact foreign exchange rate change cash flow accordingly company enter forward foreign exchange contract protect value certain foreign currency asset liability hedge future foreign currency transaction primarily relate product cost gain loss contract offsetby gain loss underlie transaction appreciation dollar december market rate increase unrealized value company forward contract million conversely depreciation dollar december market rate decrease unrealized value company forward contract million scenario gain loss forward contract offset gain loss underlie transaction impact future anticipate earning cash flow company hedge exposure fluctuation currency exchange rate effect certain asset liability foreign currency enter currency swap contract change spread foreign interest rate companys interest rate sensitive financial instrument increase decrease unrealized value company swap contract approximately million scenario maturity gain loss swap contract offset gain loss underlie transaction impact future anticipate cash flow company enter financial instrument trade speculative purpose company policy enter contract party investment grade credit rating counterpartie contract major financial institution significant concentration exposure counterparty management believe risk loss remote fiscal second quarter company enter credit support agreement csa certain derivative counterpartie establish collateral threshold base respective credit rating netting agreement note consolidated financial statement additional detail credit support agreement company invest fix rate float rate interest earn security carry degree interest rate risk fair market value fix rate security adversely impact rise interest rate float rate security produce income predict interest rate fall basis point change spread company interest rate sensitive investment increase decrease unrealized value cash equivalent current marketable security approximately million company access substantial source fund numerous bank worldwide september company secure new day credit facility total credit available company approximate billion expire september interest charge borrowing credit line agreement base bid provide bank prime rate london interbank offer rate libor applicable market rate allow term agreement plus applicable margin commitment fee agreement material total borrowing end billion billion respectively decrease borrowing retirement debt net debt cash current marketable security net debt billion compare net debt billion total debt represent total capital shareholder equity total debt total capital shareholder equity share end compare yearend summary borrowing find note consolidated financial statement contractual obligation commitment company contractual obligation primarily recently enact tax legislation lease debt unfunded retirement plan significant obligation satisfy obligation company use cash operation follow table summarize company contractual obligation aggregate maturity december note consolidated financial statement detail interest unfunded tax legislation debt debt retirement dollar millions tcja obligation obligation plan lease total total tax matter note consolidated financial statement retirement plan postemployment medical benefit information note consolidated financial statement table include activity relate business combinationsdividend company increase dividend consecutive year cash dividend pay share share information critical accounting policy estimate management discussion analysis result operation financial condition base company consolidate financial statement prepare accordance accounting principle generally accept gaap preparation financial statement require management estimate assumption affect amount report revenue expense asset liability relate disclosure actual result differ estimate company believe understand certain key accounting policy estimate essential achieve insight company operating result financial condition key accounting policy include revenue recognition income taxis legal selfinsurance contingency valuation longlive asset assumption determine amount record pension employee benefit plan account stock base awards revenue recognition company recognize revenue product sale obligation term contract customer satisfy generally occur transfer control good customer company global payment term typically day provision certain rebate sale incentive trade promotion coupon product return discount customer account variable consideration record reduction sale note consolidated financial statement accounting standard update relate revenue adopt product discount grant base term arrangement direct indirect market participant market condition include consideration competitor pricing rebate estimate base contractual term historical experience patient outcome trend analysis project market condition market serve company evaluate market condition product group product primarily analysis wholesaler thirdparty sellthrough market research datum internally generate information sale return estimate record base historical sale return information product exhibit unusual sale return pattern date competition marketing matter specifically investigate analyze accounting sale return accrual sale return allowance represent reserve product return expiration destruction field specific area product recall sale return reserve base historical return trend product market percent gross sale accordance company accounting policy company generally issue credit customer return good company sale return reserve account accordance gaap guidance revenue recognition right return exist sale return reserve record sale value sale return consumer pharmaceutical segment exclusively resalable sale return certain franchise medical device segment typically resalable material company infrequently exchange product inventory return product sale return reserve total company approximately annual net trade sale fiscal reporting year promotional program product list allowance cooperative advertising arrangement record period relate sale continue promotional program include coupon volumebase sale incentive program redemption cost consumer coupon base historical redemption experience product value volumebase incentive program base estimate sale volume incentive period record product sell arrangement evaluate determine appropriate amount defer record reduction revenue company earn profitshare payment collaborative arrangement certain product include sale customer year present profitshare payment approximately total revenue include sale customer addition company enter collaboration arrangement contain multiple revenue generating activity amount collaborative partner arrangement recognize activity perform deliver base relative selling price upfront fee receive arrangement defer recognize performance period note consolidated financial statement additional disclosure collaboration reasonably likely change assumption calculate accrual rebate return promotion anticipate material effect financial statement company currently disclose impact change assumption quarterly annual filing material financial statement impactbelow table progression accrue rebate return promotion reserve doubtful account reserve cash discount segment business fiscal year end december december consumer segment balance begin balance dollar million period accrual paymentscredit end period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million december million december record contra asset pharmaceutical segment balance begin balance dollar million period accrual paymentscredit end period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million december million december record contra asset include adjustment medical device segment balance begin balance dollar million period accrual paymentscredit end period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million december million december record contra asset certain prior period amount reclassify conform current year presentation income taxis income taxis record base amount refundable payable current year include result difference gaap accounting tax reporting record defer tax asset liability company estimate defer tax asset liability base enact tax regulation rate future change tax law rate affect record defer tax asset liability company unrecognize tax benefit uncertain tax position company follow gaap prescribe recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return management believe change estimate material effect company result operation cash flow financial position company record defer tax liability undistribute earning prior december international subsidiary company provide defer taxis undistribute earning subsequent january certain international subsidiary earning consider indefinitely reinveste company intend continue reinvest earning international operation company decide later date repatriate earning company require provide net tax effect amount company estimate total tax effect repatriation approximately billion current enact tax law regulation current currency exchange rate note consolidated financial statement information income taxis legal self insurance contingency company record accrual contingency include legal proceeding product liability claim arise normal course business accrual base management judgment probability loss applicable actuarially determined estimate company self insurance whollyowne captive insurance company addition accrual self insurance programclaim exceed insurance coverage accrue loss probable amount reasonably estimate company follow provision gaap recording litigation relate contingency liability record loss probable reasonably estimate good estimate loss range accrue estimate range well minimum accrue note consolidated financial statement information product liability legal proceeding longlive intangible asset company assess change economic condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset assumption estimate change time necessary company record impairment charge employee benefit plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide plan base assumption discount rate expect return plan asset mortality rate expect salary increase health care cost trend rate attrition rate note consolidated financial statement detail rate effect rate change health care cost trend companys result operation stock base compensation company recognize compensation expense associate issuance equity instrument employee service base type equity instrument fair value estimate date grant blackschole option valuation model combination blackschole option valuation model monte carlo valuation model expense financial statement service period input assumption determine fair value expect life expect volatility riskfree rate expect dividend yield performance share unit fair market value calculate component goal date grant fair value sale earning share goal performance share unit estimate date grant fair market value share time award discount dividend pay performance share unit vest period fair value relative total shareholder return goal performance share unit estimate date grant monte carlo valuation model note consolidated financial statement additional information new accounting pronouncement refer note consolidated financial statement recently adopt accounting pronouncement recently issue accounting pronouncement adopt december economic market factor company aware product environment decade policymaker consumer business express concern rise cost health care response concern company longstande policy pricing product responsibly period weight average compound annual growth rate company net price increase health care product prescription overthecounter drug hospital professional product consumer price index cpi company operate certain country economic condition continue present significant challenge company continue monitor situation appropriate action inflation rate continue effect worldwide economy consequently way company operate company account operation argentina begin fiscal quarter venezuela highly inflationary prior threeyear cumulative inflation rate surpass material impact company result period face increase cost company strive maintain profit margin cost reduction program productivity improvement periodic price increase june united kingdom hold referendum voter approve exit european union commonly refer brexit january formally exit give lack comparable precedent unclear ultimate financial trade regulatory legal implication withdrawal brexit create global political economic uncertainty cause consequence volatility exchange rate interest rate additional cost containment thirdparty payor change regulation company currently believe related effect material impact company consolidate financial position operating result december business company subsidiary represent company consolidated asset fiscal month revenue respectively company expose fluctuation currency exchange rate change value dollar compare foreign currency company sale income expense increase decrease translation foreign sale approximately million net income approximately million government world consider proposal change tax law include increase decrease exist statutory tax rate change statutory tax rate country result revaluation company defer tax asset liability relate particular jurisdiction period new tax law isenacte change result expense benefit record company consolidate statement earning company closely monitor proposal arise country operate change statutory tax rate occur time related expense benefit record material fiscal quarter year law change enact discussion federal act tax reform ahv finance swiss tax reform provision taxis income management discussion analysis financial condition result operation company face worldwide health care change continue result pricing pressure include health care cost containment government legislation relate sale promotion reimbursement health care product change behavior spend pattern purchaser health care product service include delay medical procedure ration prescription medication reduce frequency physician visit forego health care insurance coverage result current global economic downturn continue impact company business company operate environment increasingly hostile intellectual property right firm file abbreviate new drug application biosimilar biological product application fda challenge coverage andor validity company patent seek market generic biosimilar form company key pharmaceutical product prior expiration applicable patent cover product event company successful defend patent claim challenge result lawsuit generic biosimilar version product issue introduce market result potential substantial market share revenue loss product result noncash impairment charge associate intangible asset risk competitor launch generic biosimilar version product issue follow regulatory approval valid patent place information discussion remicade relate case litigation filer abbreviate new drug application note consolidated financial statement legal proceeding johnson johnson certain subsidiary involve lawsuit claim product liability intellectual property commercial matter governmental investigation legal proceeding arise time time ordinary course business company record accrual loss contingency associate legal matter probable liability incur loss reasonably estimate december company determine liability associate certain litigation matter probable reasonably estimate company accrue matter continue monitor related legal issue adjust accrual warrant base new information development accordance asc litigation regulatory matter discuss loss probable reasonably possible company unable estimate possible loss range loss amount accrue amount accrue legal contingency result complex series judgment future event uncertainty rely heavily estimate assumption include time relate payment ability estimate judgment affect factor include thing damage seek proceeding unsubstantiated indeterminate scientific legal discovery commence complete proceeding early stage matter present legal uncertainty significant fact dispute procedural jurisdictional issue uncertainty unpredictability number potential claim numerous party involve extent adverse verdict render company company record accrual loss determine probable reasonably estimate company opinion base examination matter experience date discussion counsel ultimate outcome legal proceeding net liability accrue company balance sheet expect material adverse effect company financial position resolution increase accrual matter report period material adverse effect company result operation cash flow period note consolidated financial statement information legal proceeding common stock company common stock list new york stock exchange symbol jnj february record holders common stock company item quantitative qualitative disclosure market risk information call item incorporate reference item management discussion analysis result operation financial condition liquidity capital resource finance market risk report note summary significant accounting policy financial instrument note consolidated financial statement include item reportitem financial statement supplementary data index audit consolidated financial statement consolidate balance sheet consolidate statement earning consolidate statement comprehensive income consolidate statement equity consolidate statement cash flow note consolidated financial statement report independent register public accounting firm management report internal control financial reporting johnson johnson subsidiaries consolidate balance sheet december december dollar million share share amount note asset current asset cash cash equivalent note marketable security note account receivable trade allowance doubtful account inventory note prepay expense receivables asset hold sale note total current asset property plant equipment net note intangible asset net note goodwill note defer taxis income note asset total asset liability shareholder equity current liability loan note payable note account payable accrue liability accrue rebate return promotions accrue compensation employee relate obligation accrue taxis income note total current liability longterm debt note defer taxis income note employee relate obligation note longterm taxis payable note liability total liability commitment contingency note shareholder equity prefer stock par value authorize unissued share common stock par value share note authorize share issue share accumulate comprehensive income loss note retain earning common stock hold treasury cost note share share total shareholder equity total liability shareholder equity note consolidated financial statement johnson johnson subsidiaries consolidate statement earning dollar share million share amount note sale customer cost product sell gross profit selling marketing administrative expense research development expense inprocess research development note interest income interest expense net portion capitalize note income expense net restructure note earning provision taxis income provision taxis income note net earning net earning share note basic diluted average share outstanding note basic diluted note consolidated financial statement johnson johnson subsidiaries consolidate statement comprehensive income dollar million note net earning comprehensive income loss net tax foreign currency translation security unrealize hold gain loss arise period reclassification earning net change employee benefit plan prior service credit cost net amortization gain loss net amortization effect exchange rate net change derivative hedge unrealize gain loss arise period reclassification earning net change comprehensive income loss comprehensive income tax effect comprehensive income fiscal year end respectively foreign currency translation million million security million employee benefit plan million million million derivative hedge million million million note consolidated financial statement johnson johnson subsidiaries consolidate statement equity dollar million note accumulate common stock treasury retain comprehensive issue stock total earning income loss balance january net earning cash dividend pay share employee compensation stock option plan repurchase common stock comprehensive income loss net tax balance december cumulative adjustment net earning cash dividend pay share employee compensation stock option plan repurchase common stock comprehensive income loss net tax balance december net earning cash dividend pay share employee compensation stock option plan repurchase common stock comprehensive income loss net tax balance december note consolidated financial statement additional detail effect cumulative adjustment retain earning note consolidated financial statement johnson johnson subsidiaries consolidate statement cash flow dollar million note cash flow operating activity net earning adjustment reconcile net earning cash flow operating activity depreciation amortization property intangible stock base compensation asset writedown gain sale assetsbusinesse defer tax provision account receivable allowance change asset liability net effect acquisition divestiture increase account receivable increasedecrease inventory increase account payable accrue liability increase current noncurrent asset increasedecrease current noncurrent liability net cash flow operating activity cash flow invest activity addition property plant equipment proceed disposal assetsbusinesse net acquisition net cash acquire note purchase investment sale investment proceed credit support agreement net cash investing activity cash flow financing activity dividend shareholder repurchase common stock proceed shortterm debt repayment shortterm debt proceed longterm debt net issuance cost repayment longterm debt proceed exercise stock optionsemployee withholding tax stock award net net cash financing activity effect exchange rate change cash cash equivalent decreaseincrease cash cash equivalent cash cash equivalent begin year note cash cash equivalent end year note supplemental cash flow datum cash pay year interest interest net capitalize income taxis supplemental schedule noncash investing financing activity treasury stock issue employee compensation stock option plan net cash proceed employee withholding tax stock award conversion debt acquisition fair value asset acquire fair value liability assume noncontrolle interest net cash pay acquisition note note consolidated financial statement note consolidated financial statement summary significant accounting policy principle consolidation consolidated financial statement include account johnson johnson subsidiaries company intercompany account transaction eliminate column row table add round percentage calculate actual nonrounde figure description company business segment company approximately employee worldwide engage research development manufacture sale broad range product health care field company conduct business virtually country world primary focus product relate human health wellbee company organize business segment consumer pharmaceutical medical device consumer segment include broad range product baby care oral care beauty overthecounter pharmaceutical womens health wound care market product market general public sell retail outlet distributor world pharmaceutical segment focus therapeutic area include immunology infectious disease neuroscience oncology pulmonary hypertension cardiovascular metabolic disease product segment distribute directly retailer wholesaler hospital health care professional prescription use medical device segment include broad range product orthopaedic surgery interventional solution cardiovascular neurovascular eye health field distribute wholesaler hospital retailer principally professional field physician nurse hospital eye care professional clinic new accounting standard recently adopt accounting standard asu lease company adopt standard begin fiscal year prospective basis update require recognition lease asset lease liability balance sheet lease obligation disclose key information leasing arrangement update require recognition lease asset lease liability lessee arrangement classify operating lease company operating lease result recognition additional asset correspond liability consolidate balance sheet material impact consolidate financial statement company determine arrangement lease contract inception establish contract convey right control use identify property plant equipment period time exchange consideration right use rou assets lease liability operating lease include asset accrue liability liability consolidate balance sheet rou asset represent right use underlie asset lease term lease liability represent obligation lease payment arise lease commitment finance lease significant include property plant equipment loan note payable longterm debt consolidate balance sheet rou assets lease liability recognize lease commencement date base present value minimum lease payment lease term company use incremental borrowing rate base information available commencement date determine present value lease payment implicit rate readily determinable lease term include option extend terminate lease option include lease term reasonably certain company exercise option operating lease expense recognize straightline basis lease term company elect follow policy election adoption use portfolio approach lease asset master service agreement exclusion short term lease balance sheet separate lease nonlease component additional disclosure note consolidated financial statement asu reclassification certain tax effect accumulate comprehensive income update allow company elect reclassify strand tax effect result tax cut job act enact december accumulate comprehensive income retain earning company elect reclassifythe income tax effect standard standard impact company consolidated financial statement asu derivative hedge topic asc update add overnight index swap ois rate base secured overnight financing rate sofr eligible benchmark interest rate permit application hedge accounting guidance effective company fiscal fourth quarter previous adoption asu impact adoption guidance material impact company consolidate financial statement relate disclosure standard impact future market sofr derivative develop time sofr hedge company financial instrument accounting standard adopt fiscal cumulative effect opening balance retain earning follow table summarize cumulative effect adjustment opening balance retain earning adoption new accounting standard mention cumulative effect adjustment increase decrease retain dollar million earning asu revenue contract customer asu financial instrument asu income taxis intraentity transfer total recently issue accounting standard adopt december asu collaborative arrangement update clarifie interaction asc collaborative arrangement asc revenue contract customer update clarify certain transaction participant collaborative arrangement account asc counterparty customer addition update preclude entity present consideration transaction collaborative arrangement revenue counterparty customer transaction update effective company fiscal year begin december interim period fiscal year asu apply retrospectively date initial application asc early adoption permit adoption standard material impact company consolidate financial statement asu financial instrument credit loss update introduce current expect credit loss cecl model require entity measure credit loss certain financial instrument financial asset include trade receivables update initial recognition reporting period entity require recognize allowance reflect entitys current estimate credit loss expect incurred life financial instrument update effective company fiscal year begin december interim period fiscal year early adoption permit adoption standard material impact company consolidate financial statement cash equivalent company classify highly liquid investment state maturity month date purchase cash equivalent highly liquid investment state maturity great month date purchase current marketable security company policy make investment commercial institution investment grade credit rating company invest cash primarily government security obligation corporate debt security money market fund reverse repurchase agreement rra rra collateralized deposit form government security obligation value company record asset liability company permit sell repledge associate collateral company policy collateral equivalent credit rating company utilize party custodian manage exchange fund ensure collateral receive maintain value rra daily basis rra state maturity great month date purchase classify marketable securitiesinvestment investment classify hold maturity investment report amortize cost realize gain loss report earning investment classify availableforsale debt security carry estimate fair value unrealize gain loss record component accumulate comprehensive income availableforsale security available current operation classify current asset classify long term management determine appropriate classification investment debt equity security time purchase reevaluate determination balance sheet date company review investment impairment adjust investment fair value earning require property plant equipment depreciation property plant equipment state cost company utilize straightline method depreciation estimate useful life asset building building equipment year land leasehold improvement year machinery equipment year company capitalize certain computer software development cost include machinery equipment incur connection develop obtain computer software internal use capitalize software cost amortize estimate useful life software generally range year company review longlive asset assess recoverability undiscounted cash flow certain event change operate economic condition occur impairment assessment perform recoverability carrying value asset asset determine impair loss measure base difference asset fair value carry value quote market price available company estimate fair value discount value estimate future cash flow revenue recognition company recognize revenue product sale obligation term contract customer satisfy generally occur transfer control good customer company global payment term typically day provision certain rebate sale incentive trade promotion coupon product return discount customer account variable consideration record reduction sale liability recognize accrue rebate return promotion consolidate balance sheet product discount grant base term arrangement direct indirect market participant market condition include consideration competitor pricing rebate estimate base contractual term historical experience patient outcome trend analysis project market condition market serve significant portion liability relate rebate sale company pharmaceutical product primarily manage care medicare medicaid program amount billion billion december december respectively company evaluate market condition product group product primarily analysis wholesaler thirdparty sellthrough market research datum internally generate information sale return estimate record base historical sale return information product exhibit unusual sale return pattern date competition marketing matter specifically investigate analyze accounting sale return accrual sale return allowance represent reserve product return expiration destruction field specific area product recall sale return reserve base historical return trend product market percent gross sale accordance company accounting policy company generally issue credit customer return good company sale return reserve account accordance gaap guidance revenue recognition right return exist sale return reserve record sale value sale return consumer pharmaceutical segment exclusively resalable sale return certain franchise medical device segment typically resalable material company infrequently exchange product inventory return product sale return reserve total company approximately annual net trade sale fiscal reporting year promotional program product list allowance cooperative advertising arrangement record thesame period relate sale continue promotional program include coupon volumebase sale incentive program redemption cost consumer coupon base historical redemption experience product value volumebase incentive program base estimate sale volume incentive period record product sell arrangement evaluate determine appropriate amount defer record reduction revenue company earn profitshare payment collaborative arrangement certain product include sale customer year present profitshare payment approximately total revenue include sale customer note consolidated financial statement disaggregation revenue shipping handle shipping handling cost incur billion billion billion respectively include sell marketing administrative expense revenue receive shipping handle sale customer period present inventory inventory state low cost net realizable value determine firstin firstout method intangible asset goodwill authoritative literature gaap require goodwill intangible asset indefinite life assess annually impairment company complete annual impairment test fiscal fourth quarter future impairment test perform annually fiscal fourth quarter soon warrant purchase inprocess research development account indefinite live intangible asset underlie project complete point intangible asset account definite live intangible asset abandon point intangible asset write partially impair intangible asset finite useful life continue amortize useful life review impairment warrant economic condition note detail intangible asset goodwill financial instrument require gaap derivative instrument record balance sheet fair value fair value exit price receive sell asset pay transfer liability fair value marketbase measurement determine assumption market participant use price asset liability authoritative literature establish threelevel hierarchy prioritize input measure fair value level high priority level low change fair value derivative record period current earning comprehensive income depend derivative designate hedge transaction type hedge transaction company document relationship hedge item derivative overall risk management strategy include reason undertake hedge transaction enter derivative objective strategy minimize foreign currency exposure impact company financial performance protect company cash flow adverse movement foreign exchange rate ensure appropriateness financial instrument manage enterprise risk associate financial institution note additional information financial instrument product liability accrual product liability claim record undiscounted basis probable liability incur liability reasonably estimate base exist information actuarially determine estimate applicable accrual adjust periodically additional information available company accrue estimate legal defense cost need defend matter cost probable reasonably estimate extent adverse verdict render company company record accrual loss determine probable reasonably estimate company self insurance whollyowne captive insurance company addition accrual self insurance program claim exceed insurance coverage accrue loss probable amount reasonably estimate research development research development expense expense incur accordance asc research development upfront milestone payment party connection research development collaboration expense incur point regulatory approval payment party subsequent regulatory approval capitalize amortize remain useful life relate product amount capitalize payment include intangible net accumulate amortization company enter collaborative arrangement typically pharmaceutical biotechnology company develop commercialize drug candidate intellectual property arrangement typically involve party active participant collaboration expose significant risk reward dependent commercial success activity collaboration usually involve activity party include research anddevelopment marketing selling distribution collaboration require upfront milestone royalty profit share payment contingent occurrence certain future event link success asset development amount collaborative partner relate development activity generally reflect reduction research development expense performance contract development service central company operation general income statement presentation collaboration follow naturetype collaboration statement earning presentation thirdparty sale product profit share payment receive sale customer royaltiesmilestone pay collaborative partner post cost product sell regulatory approval royalty receive collaborative partner income expense net upfront payment milestone pay collaborative partner research development expense preregulatory approval research development payment collaborative partner research development expense research development payment receive reduction research development expense collaborative partner milestone capitalize intangible asset amortize cost product sell useful life year present individual project represent great total annual consolidated research development expense company number product compound develop collaboration strategic partner include xarelto codevelope bayer healthcare imbruvica develop collaboration comarketed pharmacyclic llc abbvie company separately company number license arrangement product compound include darzalex license genmab advertising cost associate advertising expense year incur include sell marketing administrative expense advertising expense worldwide comprise television radio print medium internet advertising billion billion billion respectively income taxis income taxis record base amount refundable payable current year include result difference gaap accounting tax reporting record defer tax asset liability company estimate defer tax asset liability base enact tax regulation rate future change tax law rate affect record defer tax asset liability future company unrecognize tax benefit uncertain tax position company follow gaap prescribe recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return management believe change estimate material effect company result operation cash flow financial position january fasb issue guidance allow company elect accounting policy record tax effect global intangible lowtaxed income gilti period tax liability generate period cost provide defer tax asset liability relate basis difference exist expect effect gilti inclusion future year reversal defer method fiscal company elect account gilti defer method defer tax amount record base evaluation temporary difference expect reverse gilti incur future period company record defer tax liability undistribute earning prior december international subsidiary company provide defer taxis undistribute earning subsequent january certain international subsidiary earning consider indefinitely reinveste company intend continue reinvest earning international operation company decide later date repatriate earning company require provide net tax effect amount company estimate total tax effect repatriation approximately billion current enact tax law regulation current currency exchange rate note consolidated financial statementsfor information income taxesnet earning share basic earning share compute divide net earning available common shareholder weight average number common share outstanding period dilute earning share reflect potential dilution occur security exercise convert common stock treasury stock method use estimate preparation consolidate financial statement conformity accounting principle generally accept require management estimate assumption affect amount report estimate accounting sale discount rebate allowance incentive product liability income taxis withhold taxis depreciation amortization employee benefit contingency intangible asset liability valuation actual result differ estimate company follow provision gaap recording litigation relate contingency liability record loss probable reasonably estimate good estimate loss range accrue estimate range well minimum accrue annual closing date company follow concept fiscal year end sunday nearest end month december normally fiscal year consist week year fiscal year consist week include additional shipping day case case reclassification certain prior period amount reclassify conform current year presentation cash cash equivalent current marketable security end fiscal year cash cash equivalent current marketable security comprise dollar millions current carry cash cash marketable equivalent security cash nonus sovereign security reverse repurchase agreement reverse repurchase agreement corporate debt security money market fund time deposit subtotal security corporate debt security subtotal available sale total cash cash equivalent current marketable security dollar million current carry cash cash marketable equivalent security cash reverse repurchase agreement reverse repurchase agreement money market fund time deposit subtotal security corporate debt security subtotal available sale total cash cash equivalent current marketable security hold maturity investment report amortize cost realize gain loss report earning available sale debt security report fair value unrealize gain loss report net taxis comprehensive income fair value government security obligation corporate debt security estimate quote broker price significant observable input carrying estimate fair value contractual maturity available sale debt security december follow cost basis fair value dollar million year year year year year total debt security company invest excess cash deposit major bank world highquality money market instrument company policy make investment commercial institution investment grade credit rating inventory end inventory comprise dollar million raw material supply good process finish good total inventory note consolidated financial statement detail asset hold sale relate divestiture property plant equipment end property plant equipment cost accumulate depreciation dollar million land land improvement building build equipment machinery equipment construction progress total property plant equipment gross accumulate depreciation total property plant equipment net note consolidated financial statement detail asset hold sale relate divestiture company capitalize interest expense cost construction facility equipment interest expense capitalize million million million respectively depreciation expense include amortization capitalize interest billion billion billion respectively retirement disposal property plant equipment cost relate amount accumulate depreciation amortization eliminate asset accumulate depreciation account respectively difference net asset value proceed record earning intangible asset goodwill end gross net amount intangible asset dollar million intangible asset definite life patent trademark gross accumulate amortization patent trademark net customer relationship intangible gross accumulate amortization customer relationship intangible net intangible asset indefinite live trademark purchase inprocess research development total intangible asset indefinite live total intangible asset net majority comprise customer relationship fiscal year company complete acquisition auris health inc record inprocess research development intangible asset billion additionally fiscal quarter company record iprd impairment charge billion remain intangible asset value relate development program investigational drug treatment respiratory syncytial virus rsv human metapneumovirus hmpv acquire acquisition alios biopharma inc impairment charge base additional information include clinical datum available lead company decision abandon development partial impairment charge billion previously record fiscal quarter relate development program algoodwill december december allocate segment business follow dollar million consumer pharmaceutical medical device total goodwill december goodwill relate acquisition goodwill relate divestiture currency translationother goodwill december goodwill relate acquisition currency translationother goodwill december goodwill billion relate divestiture lifescan business goodwill billion relate divestiture advanced sterilization product business close pende classify asset hold sale consolidate balance sheet december weight average amortization period patent trademark year weight average amortization period customer relationship intangible asset year amortization expense amortizable asset include cost product sell billion billion billion tax fiscal year end december december december respectively intangible asset writedown include income expense net estimate amortization expense approve product tax succeed year approximately dollar million note consolidated financial statement additional detail relate acquisition divestiture fair value measurement company use forward foreign exchange contract manage exposure variability cash flow primarily relate foreign exchange rate change future intercompany product thirdparty purchase material denominate foreign currency company use cross currency interest rate swap manage currency risk primarily relate borrowing type derivative designate cash flow hedge additionally company use interest rate swap instrument manage interest rate risk relate fix rate borrowing derivative designate fair value hedge company use cross currency interest rate swap forward foreign exchange contract designate net investment hedge additionally company use forward foreign exchange contract offset exposure certain foreign currency asset liabilitie forward foreign exchange contract designate hedge change fair value derivative recognize earning offset current earning effect relate foreign currency asset liability company enter derivative financial instrument trade speculative purpose contain credit risk relate contingent feature company maintain credit support agreement csa certain derivative counterpartie establish collateral threshold base respective credit rating netting agreement december total cash collateral hold company credit support agreement csa amount million net primarily related net investment hedge ongoing basis company monitor counterparty credit rating company consider credit nonperformance risk low company primarily enter agreement commercial institution investment grade credit rating refer table significant financial asset andliabilitie measure fair value contain footnote receivables payable commercial institution december company notional amount outstanding forward foreign exchange contract cross currency interest rate swap billion billion respectively december company notional amount outstanding forward foreign exchange contract cross currency interest rate swap interest rate swap billion billion billion respectively derivative instrument record balance sheet fair value change fair value derivative record period current earning comprehensive income depend derivative designate hedge transaction type hedge transaction designation cash flow hedge entrance date derivative contract inception derivative expect highly effective foreign exchange contract designate cash flow hedge account forward method gainslosse associate contract recognize income statement hedge item impact earning change fair value derivative record accumulate comprehensive income underlie transaction affect earning reclassify earning account hedge transaction gain loss associate interest rate swap change fair value hedge debt attributable change interest rate record interest expense period occur effect immaterial fiscal year end december december gain loss net investment hedge account currency translation account accumulate comprehensive income portion exclude effectiveness testing record interest income expense spot method ongoing basis company assess derivative continue highly effective offset change hedge item derivative long expect highly effective hedge accounting discontinue company designate euro denominate note issue date range net investment hedge company investment certain international subsidiary use euro functional currency order reduce volatility cause change exchange rate december balance defer net loss derivative include accumulate comprehensive income million aftertax additional information consolidated statement comprehensive income note company expect substantially amount relate forward foreign exchange contract reclassify earning month result transaction expect occur period maximum length time company hedge transaction exposure month exclude interest rate contract net investment hedge ultimately realize earning differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity derivative follow table summary activity relate derivative hedge fiscal year end december december net tax december december cost interest cost interest product income income product income income sale sell expense expense expense sale sell expense expense expense dollar million effect fair value net investment cash flow hedge gain loss net investment hedging relationship cross currency interest rate swap contract gain loss recognize income derivative exclude effectiveness testing gain loss recognize aoci gain loss cash flow hedging relationship forward foreign exchange contract gain loss reclassify aoci income gain loss recognize aoci cross currency interest rate swap contract gain loss reclassify aoci income gain loss recognize aoci fiscal year end december december follow amount record consolidated balance sheet cumulative fair value hedge line item consolidate balance sheet carrying hedge liability adjustment include carrying hedge item include hedge liability dollar million december december december december current portion longterm debt follow table effect derivative designate hedge instrument fiscal year end december december location gain loss gainloss recognize income recognize dollar million derivative income derivative derivative designate hedge december december instrument income expense foreign exchange contract follow table effect net investment hedge fiscal year end december december gainloss location gain loss reclassify gainloss reclassify recognize accumulate accumulate oci accumulate oci comprehensive income income income december december december december dollar millions interest income expense debt cross currency interest rate swap interest income expense company hold equity investment readily determinable fair value equity investment readily determinable fair value company measure equity investment readily determinable fair value cost minus impairment plus minus change result observable price change orderly transaction identical similar investment issuer follow table summary activity relate equity investment fiscal year end december december december december change fair value reflect sale non current dollar million carry value net income purchasesother carry value asset equity investment readily determinable value equity investment readily determinable value december december change fair value reflect sale non current dollar million carry value net income purchasesother carry value assetsequity investment readily determinable value equity investment readily determinable value record incomeexpense include impact currency fiscal year end december december equity investment readily determinable market value million million respectively change fair value reflect net income result impairment million million respectively change fair value reflect net income change observable price fair value exit price receive sell asset pay transfer liability fair value marketbase measurement determine assumption market participant use price asset liability accordance asc threelevel hierarchy prioritize input measure fair value level hierarchy describe level high priority level low fair value derivative financial instrument forward foreign exchange contract interest rate contract aggregation currency future cash flow discount present value prevail market interest rate subsequently convert dollar current spot foreign exchange rate company believe fair value derivative instrument materially differ amount realize settlement maturity change fair value material effect company result operation cash flow financial position company hold equity investment classify level debt security classify level company hold acquisition relate contingent liability base certain regulatory commercial event classify level value determine discount cash flow methodology similar technique determination fair value require significant judgment estimation follow level input measure fair value level quote price active market identical asset liability level significant observable input level significant unobservable input company significant financial asset liability measure fair value fiscal year end december december follow dollar million level level level total total derivative designate hedge instrument asset forward foreign exchange contract interest rate contract total liability forward foreign exchange contract interest rate contract total derivative designate hedge instrument asset forward foreign exchange contract liability forward foreign exchange contract available sale investment equity investment debt security liability contingent consideration gross net derivative reconciliation dollar million total gross asset credit support agreement csa total net asset total gross liability credit support agreement csa total net liability summarize information change liabilitie contingent consideration follow dollar million begin balance change estimate fair value addition payment end balance asset liability classify level exception equity investment million classify level contingent consideration million classify level include million million noncurrent asset fiscal year end december december respectively include million noncurrent liability fiscal year end december include cross currency interest rate swap interest rate swap classify noncurrent asset classify cash equivalent current marketable security include million primarily related auris health million million classified noncurrent liability december december december respectively include million classify current liability december amount record primarily research development expense note financial asset liability hold carrying consolidate balance sheet borrowing component longterm debt follow effective effective rate rate dollar million note euro euro note note note zero coupon convertible subordinated debenture debenture note note note note note euro euro note debenture note note note euro euro note gbp gbp note note note note euro euro note note debenture note note euro euro note note note debenture note debenture note note note note note subtotal current portion total longterm debt weight average effective rate translation rate december translation rate december excess fair value carry value debt billion billion fair value longterm debt estimate market price corroborate quote broker price significant observable input company access substantial source fund numerous bank worldwide september company secure new day credit facility total credit available company approximate billion expire september interest charge borrowing credit line agreement base bid provide bank prime rate london interbank offer rate libor applicable market rate allow term agreement plus applicable margin commitment fee agreement material company continue access liquidity commercial paper market shortterm borrowing current portion longterm debt amount approximately billion end billion current portion longterm debt remainder principally represent local borrowing international subsidiary company continue access liquidity commercial paper market shortterm borrowing current portion longterm debt amount approximately billion end billion current portion long term debt remainder principally represent local borrowing international subsidiary aggregate maturity longterm debt obligation commence dollar million income taxis provision taxis income consist dollar million currently payable tax international taxis total currently payable defer taxis international taxis total defer provision taxis income include billion defer tax expense adoption defer method account giltia comparison income tax expense statutory rate company effective tax rate follow dollar million international earning taxis income tax rate statutory rate international operation tax international income tax benefit sharebase compensation tcja relate impact effective rate period present company subsidiary operate puerto rico tax incentive international operation reflect impact operation jurisdiction statutory tax rate different particularly ireland switzerland puerto rico favorable impact effective tax rate compare statutory rate include tax cost relate revaluation defer tax balance relate change belgian statutory tax rate increase tax provision approximately include impact gilti tax foreignderive intangible income deduction foreign income taxable tax code represent impact adjustment balance originally record tcja provisional tax charge information provide include state local taxis provisionally record tcja provisional charge approximately total effective tax rate tax rate decrease compare fiscal year tax rate addition impact swiss tax reform discuss detail primary driver net decrease follow company reorganize ownership structure certain whollyowne international subsidiary fiscal fourth quarter result reduction certain withholding local taxis previously recognize provisional tax cut job act tcja tax charge fiscal year finalize fiscal year follow completion restructuring approval applicable local authority company reverse defer tax liability billion relate defer tax asset billion foreign tax credit net defer tax benefit billion decrease annual effective tax rate benefit reflect tcja relate impact company effective tax rate reconciliation impact agreement principle settle opioid litigation billion note consolidated financial statement reduce earning taxis effective tax rate decrease company annual effective tax rate approximately december fiscal year treasury issue final foreign tax credit regulation result company revise foreign tax credit initially record fiscal year provisional tcja tax charge result company record increase defer tax asset relate foreign tax credit approximately billion annual effective tax rate benefit reflect tcja relate impact company effective tax rate reconciliation company reassess uncertain tax position relate current irs audit increase unrecognized tax benefit billion liability increase annual effective tax rate approximately section unrecognized tax benefit additional information position relate uncertain tax international transfer pricing expense classify international operation company effective tax rate reconciliation subsequent december company receive agree notice propose adjustment nopas irs company believe adequately reserve potential exposure onetime tax impact result cumulative net tax benefit annual effective tax rate item include lifescan divestiture adjustment provisional tcja tax charge acceleration certain tax deduction tax return income high tax jurisdiction relative low tax jurisdiction compare september swiss parliament approve federal act tax reform ahv financing traf public referendum hold switzerland approve federal reform proposal fiscal quarter swiss federal council enact traf effective january federal transitional provision traf allow company certain condition adjust tax basis adjustment fair value stepup tax depreciation amortization purpose result deduction transitional period subsequent adjustment company asset tax basis require review approval tax authority traf provide parameter enable swiss canton establish localize tax rate regulation company new cantonal tax parameter include favorable tax benefit patent additional research development tax deduction cantonal transitional provision traf expect allow company elect tax basis stepup similar federal transition benefit alternative statutory tax rate period exceed year company currently operation locate swiss canton enactment uniform substantive nature legislation time enactment company record net tax expense billion increase effective tax rate fiscal year approximately net tax expense relate federal certain cantonal enactment fiscal year consist follow provision approximately billion tax expense relate remeasurement swiss defer tax asset liability change federal cantonal tax rate enactment occur december expense reflect international operation company effective tax rate reconciliation billion defer tax asset relate estimate value federal tax basis stepup company swiss subsidiary asset benefit reflect international operation company effective tax rate reconciliation approximately million defer tax expense relate gilti defer tax liability result remeasurement swiss defer tax asset liability new defer tax asset federal stepup benefit reflect tax international income company effective tax rate reconciliation fiscal fourth quarter swiss federal tax administration issue authoritative guidance require company decrease estimate value federal tax basis stepup approximately billion determination fiscal quarter authoritative guidance relevant swiss tax authority issue future additional revision require fiscal period issue company currently assess apply approval elective transition provision canton include discussion local tax authority application new law company record estimate impact transitional provision base well available information canton enactment occur company receive final tax ruling december canton company maintain significant operation enact traf legislation amount record fiscal year include estimate unenacted legislation february public referendum legislative change hold canton legislation approve voter formal enactment expect fiscal half company elect transitional provision canton net financial benefit estimate billion billion fiscal half tax cut job act tcja fiscal year united states enact law new tax legislation tcja law include provision comprehensive overhaul corporate income tax code include reduction statutory corporate tax rate effective january legislation eliminate reduce certain corporate income tax deduction introduce new provision tax certain foreign income previously tax united states tcja include provision tax previously undistribute earning company locate foreign jurisdiction undistribute earning form cash cash equivalent tax rate earning tax rate tax payable year accrue interest payment begin continue remain balance end fiscal year approximately billion billion classified noncurrent reflect longterm taxis payable company balance sheet balance account relate receivables tax authority expect receive month fourth quarter company record provisional tax cost approximately billion consist primarily follow component billion charge previously undistribute foreign earning december billion defer tax liability foreign local withholding taxis offset billion defer tax asset foreign tax credit repatriation substantially earning billion tax benefit relate remeasurement defer tax asset liability impact tcja unrecognized tax benefit billion charge state local taxis repatriation foreign earning fiscal year company complete assessment finalize accounting impact tcja company record net adjustment component provisional charge approximately billion revision base update estimate additional analysis management apply interpretative guidance issue department treasury fact circumstance exist tcja enactment date charge primarily relate additional defer tax liability foreign local withholding taxis remain balance undistribute foreign earning december provide provisional charge tcja include provision tax gilti gilti describe excess shareholder total net foreign income deem return tangible asset provide tcja fiscal year company elect treat gilti period expense defer method record defer tax cost approximately billion fiscal year relate fact circumstance exist date tcja enactment note information income taxis accounting policy company reorganize ownership structure certain foreign subsidiary result reduction certain foreign withholding taxis recognize provisional tcja tax charge fourth quarter follow completion restructuring result clarification swiss tax authority applicability withholding tax repatriation certain earning company reverse defer tax liability billion relate defer tax asset billion foreign tax credit net defer tax benefit billion benefit reflect tcja relate impact company effective tax rate reconciliation effective tax rate decrease compare effective tax rate primarily drive approximately billion provisional tax charge record fourth quarter impact belgian statutory tax rate change increase effective rate additional driver annual effective tax reduction statutory corporate tax rate include effect tax election result acceleration certain deduction tax return impact accelerate deduction decrease annual effective tax rate approximately impact adjustment provisional tcja charge include staff accounting bulletin sab adjustment internal restructuring decrease effective tax rate approximately gilti tax increase annual effective tax rate approximately exclude impact sab adjustment adoption defer method gilti tax benefit receive stockbased compensation fiscal reduce effective tax rate respectively fourth quarter company complete divestiture lifescan business note consolidated financial statement increase company annual effective tax rate approximately income high tax jurisdiction relative low tax jurisdiction compare temporary difference carryforward follow defer tax defer tax dollar million asset liability asset liability employee relate obligation stock base compensation depreciation amortization nondeductible intangible international capitalize tax reserve liabilitie income report tax purpose net operating loss carryforward international undistributed foreign earning global intangible lowtaxed income miscellaneous international miscellaneous total deferred income taxis company whollyowne international subsidiary cumulative net loss company believe likely subsidiary generate future taxable income sufficient utilize defer tax asset follow table summarize activity relate unrecognized tax benefit dollar million begin year increase relate current year tax position increase relate prior period tax position decreases relate prior period tax position settlement lapse statute limitation end year million decrease relate tcja unrecognized tax benefit billion december recognize affect company annual effective tax rate company conduct business file tax return numerous country currently tax audits progress number tax authority respect united states internal revenue service irs complete audit tax year currently audit tax year company currently expect completion audit settlement relate tax liability fiscal year december company classify unrecognized tax benefit relate interest approximately billion current liability accrue taxis income line consolidate balance sheet expect pay month respect irs audit subsequent december company payment approximately billion treasury relate estimate tax audit liability anticipation final settlement later fiscal completion tax audit result additional adjustment company unrecognized tax benefit liability major jurisdiction company conduct business year remain open tax audit year company believe possible tax audits complete month tax authority jurisdiction outside united states company able provide reasonably reliable estimate time future tax payment relate uncertain tax positionsthe company classifie liabilities unrecognize tax benefit relate interest penalty longterm liability previously note amount relate current united states irs audit interest expense penalty relate unrecognized tax benefit classify income tax expense company recognize tax interest expense million million million respectively total accrue interest million million respectively employee relate obligation end employee relate obligation record consolidated balance sheet dollar million pension benefit postretirement benefit postemployment benefit defer compensation total employee obligation current benefit payable employee relate obligation noncurrent prepay employee relate obligation million million respectively include asset consolidate balance sheet pension benefit plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide company provide postretirement benefit primarily health care eligible retire employee dependent international employee cover governmentsponsored program cost company significant retirement plan benefit employee hire january primarily base employee compensation year retirement number year service company announce define benefit plan amend adopt new benefit formula effective employee hire january benefit calculate new formula base employee compensation total year service international subsidiary plan fund deposit trustee annuity purchase group contract reserve provide company typically fund retiree health care benefit advance discretion company right modify plan future company december december respectively measurement date international retirement benefit plan net periodic benefit cost company define benefit retirement plan benefit plan include follow component retirement plan benefit plan dollar million service cost interest cost expect return plan asset amortization prior service cost credit recognize actuarial loss curtailment settlement net periodic benefit cost amount expect recognize net periodic benefit cost come year company define benefit retirement plan postretirement plan dollar million amortization net transition obligation amortization net actuarial loss amortization prior service credit unrecognized gain loss pension plan amortize average remain future service plan plan active employee amortize average life expectancy amortization gain loss benefit plan determine corridor great market value asset accumulate postretirement benefit obligation total unamortized gain loss excess corridor amortize average remain future service prior service costsbenefit pension plan amortize average remain future service plan participant time plan amendment prior service costbenefit benefit plan amortize average remain service eligibility age plan participant time plan amendment follow table represent weightedaverage actuarial assumption retirement plan benefit plan worldwide benefit plan net periodic benefit cost service cost discount rate interest cost discount rate rate increase compensation level expect longterm rate return plan asset benefit obligation discount rate rate increase compensation level company discount rate determine consider current yield curve represent high quality longterm fix income instrument result discount rate consistent duration plan liabilitie company methodology determine service interest cost use duration specific spot rate yield curve plan liability cash flow expect rate return plan asset assumption represent company assessment longterm return diversify investment portfolio globally assessment determine projection external financial source longterm historical average actual return asset class asset class allocation market follow table display assume health care cost trend rate individual health care plan health care cost trend rate assume year rate cost trend rate assume decline ultimate trend year rate reach ultimate trend rate onepercentagepoint change assume health care cost trend rate follow effect onepercentage onepercentagedollar million point increase point decrease health care plan total interest service cost postretirement benefit obligation follow table set forth information relate benefit obligation fair value plan asset yearend company define benefit retirement plan postretirement plan retirement plan benefit plan dollar million change benefit obligation project benefit obligation begin year service cost interest cost plan participant contribution amendment actuarial gain loss divestiture acquisition curtailment settlement restructure benefit pay plan asset effect exchange rate project benefit obligation end year change plan asset plan asset fair value begin year actual return plan asset company contribution plan participant contribution settlement divestiture acquisition benefit pay plan asset effect exchange rate plan asset fair value end year fund status end year amount recognize company balance sheet consist follow noncurrent asset current liability noncurrent liability total recognize consolidated balance sheet end year amount recognize accumulate comprehensive income consist follow net actuarial loss prior service cost credit unrecognized net transition obligation total tax effect accumulate benefit obligation end year company offer voluntary lumpsum payment option certain eligible employee vest participant qualify define benefit pension plan distribution lumpsum complete end fiscal distribute approximately million retirement plan benefit plan dollar million amount recognize net periodic benefit cost comprehensive income net periodic benefit cost net actuarial gain loss amortization net actuarial loss prior service cost credit amortization prior service cost credit effect exchange rate total lossincome recognize comprehensive income tax total recognize net periodic benefit cost comprehensive income company plan continue fund qualified plan comply pension protection act international plan fund accordance local regulation additional discretionary contribution deem appropriate meet longterm obligation plan certain plan fund common practice funding provide economic benefit consequently company pension plan fund company contribute million million international pension plan respectively follow table display fund status company qualified nonqualified pension plan international fund unfunded pension plan december december respectively plan international plan qualified plan nonqualifie plan fund plan unfunded plan dollar million plan asset project benefit obligation accumulate benefit obligation fund status project benefit obligation accumulate benefit obligation plan accumulate benefit obligation excess plan asset accumulate benefit obligation project benefit obligation plan asset billion billion billion respectively end billion billion billion respectively end follow table display project future benefit payment companys retirement benefit plan dollar million project future benefit payment retirement plan benefit plan follow table display project future minimum contribution unfunded retirement plan amount donot include discretionary contribution company elect future dollar million project future contribution pension plan oversee local committee board responsible overall administration investment pension plan determine investment policy strategy goal committee board consider factor include local pension rule regulation local tax regulation availability investment vehicle separate account commingle account insurance fund etc funded status plan ratio active retiree duration liability relevant factor include diversification liquidity local market liquidity base currency majority company pension fund open new entrant expect ongoing plan permit investment primarily liquid andor list little reliance illiquid nontraditional investment hedge fund companys retirement plan asset allocation end target allocation follow percent target plan asset allocation worldwide retirement plan equity security debt security total plan asset determination fair value plan asset plan establish welldocumented process determine fair value fair value base quote market price available list price quote available fair value base model primarily use input marketbase independently source market parameter include yield curve interest rate volatilitie equity debt price foreign exchange rate credit curve plan believe valuation method appropriate consistent market participant use different methodology assumption determine fair value certain financial instrument result different estimate fair value report date valuation hierarchy authoritative literature establish threelevel hierarchy prioritize input measure fair value level hierarchy describe table level high priority level low net asset value nav base value underlie asset own fund minus liability divide number share outstanding financial instrument categorization valuation hierarchy base low level input significant fair value measurement follow description valuation methodology investment measure fair value shortterm investment fund cash quote shortterm instrument value closing price hold deposit custodian bank investment investment vehicle value nav provide administrator fund nav quote price market active classify level government agency security limit number investment value closing price report major market individual security trade quote price available active market investment classify level valuation hierarchy quote market price available specific security fair value estimate pricing model quote price security similar characteristic discount cash flow quote market price security available active market classify level debt instrument limit number investment value closing price report major market individual security trade quote price available active market investment classify level quote market price available specific security fair value estimate pricing model quote price security similar characteristic discount cash flow classify level level debt instrument price base unobservable input equity security equity security value closing price report major market individual security trade substantially equity security classify level valuation hierarchy commingle fund investment vehicle value nav provide fund administrator asset level category quote market price insurance contract instrument issue insurance company fair value base negotiate value underlie investment hold separate account portfolio consider credit worthiness issuer underlie investment government assetbacke fix income security general insurance contract classify level quote price observable input pricing asset asset represent primarily limit partnership investment vehicle value nav provide fund administrator asset exchange list actively trade classified level inactively trade asset classify level follow table set forth retirement plan investment measure fair value december december quote price significant active significant investment market observable unobservable measure net identical asset input inputsa asset value level level level total asset dollar million shortterm investment fund government agency security debt instrument equity security commingle fund insurance contract asset investment fair value athe activity level asset significant year present company benefit plan unfunded commingle fund level million million shortterm investment fund level million million december december respectively fair value johnson johnson common stock directly hold plan asset million total worldwide plan asset december million total worldwide plan asset december saving plan company voluntary saving plan design enhance exist retirement program cover eligible employee company match percentage employee contribution consistent provision plan heshe eligible total company match contribution plan million million million respectively capital treasury stock change treasury stock treasury stock amount million treasury stock share thousand share balance january employee compensation stock option plan repurchase common stock balance december employee compensation stock option plan repurchase common stock balance december employee compensation stock option plan repurchase common stock balance december aggregate share common stock issue approximately share end cash dividend pay share compare dividend share share december company announce board director approve share repurchase program authorize company purchase billion company share common stock share repurchase program complete september october company announce board director approve share repurchase program authorize company purchase billion company share common stock share repurchase program complete july accumulate comprehensive income loss component comprehensive income loss consist follow total gain accumulate foreign loss currency gainloss employee derivative comprehensive dollar million translation security benefit plan hedge income loss january net change december cumulative adjustment retain earning net change december net change december adoption asu financial instrument amount accumulate comprehensive income present net relate tax impact foreign currency translation adjust income taxis relate permanent investment international subsidiary additional detail oncomprehensive income consolidated statement comprehensive income detail reclassification accumulate comprehensive income gainloss security reclassification release income expense net employee benefit plan reclassification include net periodic benefit cost note additional detail gainloss derivative hedge reclassification earning record account hedge transaction note additional detail international currency translation translation subsidiary operate nonus dollar currency company determine local currency international subsidiary functional currency highly inflationary economy define compound cumulative rate inflation past year substantial portion cash flow local currency majority company subsidiary local currency functional currency consolidate international subsidiary balance sheet currency effect record component accumulate comprehensive income equity account include result translate certain balance sheet asset liability current exchange rate account historical rate locate highly inflationary economy argentina venezuela translation balance sheet account highly inflationary economy reflect operating result rollforward change foreign currency translation adjustment include note net currency transaction gain loss include income expense loss million million million respectively earning share follow reconciliation basic net earning share dilute net earning share fiscal year end december december december millions share amount basic net earning share average share outstanding basic potential share exercisable stock option plan share repurchase treasury stock method convertible debt share adjust average share outstanding diluted diluted net earning share dilute net earning share calculation include dilutive effect convertible debt offset relate reduction interest expense million aftertax diluted net earning share calculation exclude insignificant number share relate stock option exercise price option great average market value company stock dilute net earning share calculation include share relate stock option exercise price option average market value company stock lease commitment company primarily operate lease space vehicle manufacture equipment datum processing equipment lease remain lease term range year year include option extend lease reasonably certain operating lease cost approximately million million million respectively cash pay amount include measurement lease liability million commitment finance lease significant supplemental information relate lease follows weight average remain lease term discount rate operating lease year weight average discount rate maturity lease liability relate operating lease approximate minimum rental payment require operating lease initial remain noncancelable lease term excess year december operating lease dollar million total lease payment interest present value lease liability supplemental information comparative period december prior adoption asu approximate future minimum rental payment require operating lease initial remain noncancelable lease term excess year dollar million total supplemental balance sheet information relate lease december follow dollar million noncurrent operating lease rightofuse asset current operating lease liability noncurrent operating lease liability total operating lease liability common stock stock option plan stock compensation agreement december company stockbase compensation plan share outstanding contract company longterm incentive plan longterm incentive plan longterm incentive plan expire april option restrict share grant subsequent date longterm incentive plan longterm incentive plan company issue million share common stock plus share cancel expire forfeit issue longterm incentive plan subsequent april share available future grant longterm incentive plan million end compensation cost charge income plan million million million respectively total income tax benefit recognize income statement sharebasedcompensation cost million million million respectively total unrecognized compensation cost million million million respectively weight average period cost recognize year year year respectively sharebase compensation cost capitalize inventory insignificant period company settle employee benefit equity issuance treasury share treasury share replenish year number share settle employee benefit equity issuances stock option stock option expire year date grant vest service period range month year option grant average high low price company common stock new york stock exchange date grant fair value option award estimate date grant blackschole option valuation model use assumption note follow table grant expect volatility represent blend rate year weekly historical overall volatility rate week average imply volatility rate base atthemoney trade johnson johnson option life year grant historical datum determine expect life option riskfree rate base treasury yield curve effect time grant average fair value option grant respectively fair value estimate base weighted average assumption riskfree rate expect volatility expect life year expect dividend yield summary option activity plan december december december change year end date present aggregate weighted intrinsic average exercise value share thousand outstanding share price dollar million share january option grant option exercise option canceledforfeite share december option grant option exercise option canceledforfeite share december option grant option exercise option canceledforfeite share december total intrinsic value option exercise million million million respectively follow table summarize stock option outstanding exercisable december share thousand outstanding exercisableaverage average exercise price range option average life exercise price option exercise price average contractual life remain year stock option outstanding december december average life year average life year respectively stock option exercisable december december average price average price respectively restrict share unit performance share unit company grant restrict share unit vest service period range month year company grant performance share unit pay share johnson johnson common stock end threeyear performance period performance share unit vest vest tie completion service period range month year achievement threeyear period equallyweighte goal directly align help drive longterm total shareholder return operational sale adjust operational earning share relative total shareholder return number share actually earn end threeyear period vary base actual performance target number performance share unit grant fourth quarter company modify restrict share unit schedule vest january march modification guarantee minimum aggregate value market value total expect payout award expect vest period commit material company overall financial position summary restrict share unit performance share unit activity plan december present outstanding outstanding restricted share performance share share thousand unit unit share december grant issue canceledforfeitedadjuste share december average fair value restrict share unit grant respectively fair market value date grant fair value restrict share unit discount dividend pay restricted share unit vest period fair value restrict share unit issue million million million respectively weight average fair value performance share unit grant calculate weighted average fair market value component goal date grant fair value sale earning share goal performance share unit estimate date grant fair market value share time award discount dividend pay performance share unit vest period fair value relative total shareholder return goal performance share unit estimate date grant monte carlo valuation model fair value performance share unit issue million million million respectively segment business geographic area sale customer change dollar million consumer baby care international worldwide beauty international worldwide oral care international worldwide otc international worldwide woman health international worldwide wound careother international worldwide total consumer international worldwide pharmaceutical immunology international worldwide remicade exports international worldwide simponi simponi aria international worldwide stelara international worldwide tremfya international worldwide immunology international worldwide infectious disease international worldwide edurant rilpivirine international worldwide prezista prezcobix rezolsta symtuza international worldwide infectious disease international worldwide neuroscience international worldwide concerta methylphenidate international worldwide invega sustenna xeplion invega trinza trevicta international worldwide risperdal consta international worldwide neuroscience international worldwide oncology international worldwide darzalex international worldwide imbruvica international worldwide velcade international worldwide zytiga abiraterone acetate international worldwide oncologyus international worldwide pulmonary hypertension international worldwide opsumit international worldwide tracleer bosentan international worldwide uptravi international worldwide international worldwide cardiovascular metabolism international worldwide xarelto international worldwide invokana invokamet international worldwide procrit eprex international worldwide international worldwide total pharmaceuticalus international worldwide medical device diabetes care international worldwide diagnostic international worldwide interventional solution international worldwide orthopaedic international worldwide hip international worldwide knee international worldwide trauma international worldwide spine international worldwide surgery international worldwide advance international worldwide generalus international worldwide specialty international worldwide vision international worldwide contact lense international worldwide surgical international worldwide total medical device international worldwide worldwide international worldwide percentage great meaningful income tax identifiable asset dollar million consumer pharmaceutical medical device total expense allocate segment general corporate worldwide total addition property depreciation plant equipment amortization dollar million consumer pharmaceutical medical device segment total general corporate worldwide total sale customer longlive asset dollar millions united states europe western hemisphere exclude asiapacific africa segment total general corporate non longlived asset worldwide total note description segment company operate export sale significant company utilize wholesaler distribute product segment represent approximately total consolidated revenue company wholesaler distribute product segment represent approximately total consolidated revenue company wholesaler distribute product segment represent approximately total consolidated revenue amount allocate segment include interest income expense general corporate income expense general corporate include cash cash equivalent marketable security consumer segment include gain billion relate company previously hold equity investment cilabo litigation expense billion restructuring charge billion pharmaceutical segment include litigation expense billion include billion relate agreement principle settle opioid litigation note consolidated financial statement additional information opioid litigation inprocess research development expense billion relate alio asset research development expense billion upfront payment relate argenx unrealize gain security billion actelion acquisition relate cost billion restructuring charge billion medical device segment include gain billion divestiture asp business restructuring relate charge billion litigation expense billion auris health acquisition relate cost billion consumer segment include gain billion divestiture nizoral litigation expense billion pharmaceutical segment include inprocess research development charge billion relate alio asset correspond contingent liability reversal billion actelion acquisition relate cost billion unrealized loss security billion gain billion divestiture certain nonstrategic pharmaceutical product medical device segment include net litigation expense billion restructuring relate charge billion amo acquisition relate cost billion gain billion divestiture lifescan business pharmaceutical segment include billion actelion acquisition integration relate cost inprocess research development expense billion litigation expense billion medical device segment include litigation expense billion restructuring relate charge billion asset impairment billion primarily relate insulin pump business billion amo acquisition relate cost medical device segment include gain billion divestiture codman neurosurgery consumer segment include gain billion divestiture compeed longlive asset include property plant equipment net respectively intangible asset goodwill net respectively select quarterly financial datum unaudite select unaudited quarterly financial datum year summarize second fourth second fourth dollar million share datum quarter quarter quarter quarter quarter quarter quarter quarter segment sale customer consumer pharmaceutical medical device total sale gross profit earning provision taxis income net earning basic net earning share dilute net earning share quarter include gain billion aftertax billion beforetax relate company previously hold equity investment cilabo inprocess research development expense million aftertax million beforetax relate alio asset litigation expense million aftertax million beforetax unrealized gain security million aftertax million beforetax restructuring relate charge million aftertax million beforetax acquisition relate cost million aftertax million beforetax second quarter include gain billion aftertax billion beforetax divestiture asp business litigation expense million aftertax million beforetax unrealized gain security million aftertax million beforetax restructuring relate charge million aftertax million beforetax acquisition relate cost million aftertax million beforetax quarter include litigation expense million aftertax million beforetax relate agreement principle settle opioid litigation restructure relate charge million aftertax million beforetax acquisition relate cost million aftertax million beforetax million benefit aftertax impact tax legislation unrealize loss security million aftertax million beforetax fourth quarter include litigation expense million aftertax million beforetax unrealized gain security million aftertax million beforetax restructuring relate charge million aftertax million beforetax million benefit aftertax impact tax legislation acquisition relate cost million aftertax million beforetax quarter include actelion acquisition relate cost million aftertax million beforetax restructuring relate charge million aftertax million beforetax second quarter include litigation expense million aftertax million beforetax restructuring relate charge million aftertax million beforetax quarter include inprocess research development expense million aftertax million beforetax relate alio asset correspond contingent liability reversal million tax restructuring relate charge million aftertax million beforetax million benefit aftertax impact tax legislation fourth quarter include litigation expense million aftertax million beforetax restructuring relate charge million aftertax million beforetax million benefit aftertax impact tax legislation acquisition divestiture certain business acquire billion cash billion liability assume acquisition account acquisition method accordingly result operation include financial statement respective date acquisition acquisition primarily include cilabo japanese company focus marketing development distribution broad range dermocosmetic cosmetic skincare product auris health inc privately hold developer robotic technology initially focus lung cancer fdacleare platform currently bronchoscopic diagnostic therapeutic procedure taris biomedical llc company specialize development novel drug delivery technology treatment bladder disease include cancer company acquire asset jointpoint inc privately hold company navigation software improve surgical outcome hip replacement excess purchase price estimate fair value tangible asset acquire amount billion assign identifiable intangible asset residual record goodwill january company acquire cilabo japanese company focus marketing development distribution broad range dermocosmetic cosmetic skincare product total purchase price approximately billion equate approximately billion exchange rate japanese yen dollar january acquisition complete series transaction include allcash tender offer acquire publicly hold share hold company share company previously hold ownership cilabo june company legal owner cilabo completion tender offer procedure japan acquire company delist tokyo stock exchange additionally fiscal quarter company recognize pretax gain record income expense net approximately billion related company previously hold equity investment cilabo company treat transaction business combination include consumer segment allocation purchase price include current period balance sheet base good estimate management preliminary subject change december fair value acquisition allocate primarily amortizable intangible asset billion goodwill billion liability billion subject subsequent valuation adjustment measurement period adjustment date acquisition billion intangible asset accrue liability defer taxis income property plant equipment offset goodwill amortizable intangible asset comprise brandtrademark customer relationship weight average life year goodwill primarily attributable synergy expect arise business acquisition expect deductible tax purpose april company complete acquisition auris health inc approximately billion net cash acquire additional contingent payment billion aggregate payable reach certain predetermine milestone auris health privately hold developer robotic technology initially focus lung cancer fdacleare platform currently bronchoscopic diagnostic therapeutic procedure company treat transaction business combination include medical device segment fair value acquisition allocate primarily amortizable nonamortizable intangible asset primarily iprd billion goodwill billion marketable security billion liability assume billion include fair value contingent payment mention subject subsequent valuation adjustment measurement period december valuation adjustment fair value contingent consideration billion probability success factor range fair value calculation reflect inherent regulatory commercial risk contingent payment iprd discount rate apply approximately goodwill primarily attributable synergy expect arise business acquisition expect deductible tax purpose december company announce agreement acquire verily stake verb surgical inc transaction close fiscal quarter verb surgical inc subsidiary johnson johnson december subsequent fiscal year end company complete acquisition right investigational compound bermekimab multiple dermatological indication certain employee xbiotech inc purchase price billion xbiotech eligible receive additional payment receipt certain commercialization authorization transaction account business combination include pharmaceutical segment certain business acquire billion cash billion liability assume acquisition account acquisition method accordingly result operation include financial statement respective date acquisition acquisition primarily include zarbees inc privately hold company leader naturallybase consumer healthcare product benevir biopharm inc benevir privatelyheld biopharmaceutical company specialize development oncolytic immunotherapy orthotaxy privatelyheld developer softwareenable surgery technology include differentiate roboticassiste surgery solution company acquire asset medicalenterprise distribution llc privately hold healthcare technology firm focus surgical procedure innovation excess purchase price estimate fair value tangible asset acquire amount billion assign identifiable intangible asset residual record goodwill certain business acquire billion cash billion liability assume acquisition account acquisition method accordingly result operation include financial statement respective date acquisition acquisition primarily include actelion ltd establish lead franchise differentiate innovative product pulmonary arterial hypertension pah abbott medical optics amo whollyowne subsidiary abbott laboratory include ophthalmic product relate cataract surgery laser refractive surgery consumer eye health neuravi limit privatelyheld medical device company develop market medical device neurointerventional therapy tearscience inc manufacturer product dedicate treat meibomian gland dysfunction sightbox inc privatelyheld company develop subscription vision care service connect consumer eye care professional supply contact lense torax medical inc privatelyheld medical device company manufacture markets linx reflux management system surgical treatment gastroesophageal reflux disease megadyne medical products inc privatelyheld medical device company develop manufacture market electrosurgical tool excess purchase price estimate fair value tangible asset acquire amount billion assign identifiable intangible asset residual record goodwill approximately billion identify value iprd primarily associate acquisition actelion ltd value iprd calculate cash flow projection discount inherent risk project company complete acquisition actelion ltd cash tender offer switzerland share amount billion net cash acquire transaction immediately prior completion acquisition actelion spin drug discovery operation earlystage clinical development asset newly create swiss biopharmaceutical company idorsia ltd shares idorsia list swiss exchange company hold share idorsia right additional idorsia equity convertible loan principal approximately billion result idorsia raise additional capital july company currently hold share idorsia right additional idorsia equity convertible loan carry value principal approximately billion convertible loan convert idorsia share subject certain restriction follow aggregate shareholding idorsia share result certain shareholder hold issue idorsia shares balance remain business day maturity date convertible loan year term idorsia undergo change control transaction maturity loan remain convert idorsia elect settle remain cash ordinary share idorsia equity investment idorsia convertible loan record asset company consolidated balance sheet company exercise option acquire act product idorsia develop resistant hypertension currently phase clinical development company enter agreement provide idorsia swiss franc denominate credit facility approximately million december idorsia drawdown credit facility actelion establish lead franchise differentiate innovative product pulmonary arterial hypertension pah highly complementary exist portfolio company addition actelion specialty inmarket medicine latestage product consistent company effort grow attractive complementary therapeutic area serve patient illness significant unmet medical need fiscal second quarter company finalize purchase price allocation actelion individual asset acquire liability assume acquisition method follow table present amount recognize asset acquire liability assume acquisition date adjustment second quarter dollar million cash cash equivalent inventory account receivable current asset property plant equipment goodwill intangible asset defer taxis noncurrent asset total asset acquire current liability defer taxis noncurrent liability total liability assume net asset acquire include adjustment million writeup acquire inventory estimate fair value adjustment date acquisition billion defer taxis billion current liability offset goodwill asset acquire record pharmaceutical segment acquisition actelion result approximately billion goodwill goodwill primarily attributable synergy expect arise acquisition goodwill expect deductible tax purpose purchase price allocation identifiable intangible asset follow dollar million intangible asset definite life patent trademark total amortizable intangible inprocess research development total intangible asset include billion relate valchlor acquire product divest fiscal second quarter patent trademark acquire comprise develop technology weight average life year primarily base patent life market product intangible asset definite life assign asset life range year inprocess research development intangible asset value technology program unapprove product value iprd calculate probability adjust cash flow projection discount risk inherent project discount rate apply acquisition account acquisition method accordingly result operation actelion report company financial statement begin june date acquisition year end december total sale net loss actelion date acquisition billion billion respectivelythe follow table provide pro forma result operation fiscal year end december actelion acquire january pro forma result include effect certain purchase accounting adjustment estimate change depreciation amortization expense acquire tangible intangible asset pro forma result include anticipate cost saving effect plan integration actelion accordingly amount necessarily indicative result acquisition occur date indicate occur future unaudited pro forma consolidated result dollar million share datum net sale net earning dilute net earning common share company record actelion acquisition relate cost tax approximately billion billion billion respectively record incomeexpense cost product sell company acquire abbott medical optics amo whollyowne subsidiary abbott laboratorie billion net cash acquire acquisition include ophthalmic product relate cataract surgery laser refractive surgery consumer eye health net purchase price primarily record amortizable intangible asset billion goodwill billion weight average life total amortizable intangible majority customer relationship approximately year goodwill primarily attributable synergy expect arise business acquisition deductible tax purpose intangible asset goodwill amount base final purchase price allocation asset acquire record medical device segment company complete acquisition synthes inc purchase price billion cash stock connection acquisition synthes inc company enter accelerated share repurchase asr agreement company settle remain liability asr agreement company believe transactions asr agreement series relate internal transaction consummate tax efficient manner accordance applicable law possible internal revenue service assert contrary position challenge transaction tax perspective challenge total purchase price synthe share treat subject applicable tax approximately statutory rate company plus interest exception actelion ltd acquisition supplemental pro forma information accordance gaap standard relate business combination goodwill intangible asset provide impact aforementione acquisition material effect company result operation cash flow financial position divestiture company divest advanced sterilization product asp business fortive corporation aggregate value approximately billion consist billion cash proceed billion retain net receivables december asset hold sale consolidate balance sheet billion inventory billion property plant equipment net billion goodwill company recognize pretax gain record income expense net approximately billion company divest lifescan inc business approximately billion retain certain net liability divestiture include nizoral roc certain nonstrategic pharmaceutical product pretax gain divestiture approximately billion company accept bind offer form strategic collaboration jabil inc world lead manufacturing service provider health care product technology product company expand year relationship jabil produce range product ethicon endosurgery depuy synthe business transaction include transfer employee manufacture site majority transfer complete minor remain december asset hold sale consolidate balance sheet billion inventory property plant equipment net december asset hold sale consolidate balance sheet billion inventory billion property plant equipment net additional detail global supply chain restructuring note consolidated financial statement company divestiture primarily include codman neurosurgery business integra lifescience holdings corporation divestiture compeed hra pharma pretax gain divestiture approximately billion legal proceeding johnson johnson certain subsidiary involve lawsuit claim product liability intellectual property commercial supplier indemnification matter governmental investigation legal proceeding arise time time ordinary course business company record accrual loss contingency associate legal matter probable liability incur loss reasonably estimate december company determine liability associate certain litigation matter probable reasonably estimate company accrue matter continue monitor related legal issue adjust accrual warrant base new information development accordance asc litigation regulatory matter discuss loss probable reasonably possible company unable estimate possible loss range loss amount accrue amount accrue legal contingency result complex series judgment future event uncertainty rely heavily estimate assumption include time relate payment ability estimate judgment affect factor include thing damage seek proceeding unsubstantiated indeterminate scientific legal discovery commence complete proceeding early stage matter present legal uncertainty significant fact dispute procedural jurisdictional issue uncertainty unpredictability number potential claim numerous party involve extent adverse verdict render company company record accrual loss determine probable reasonably estimate company opinion base examination matter experience date discussion counsel ultimate outcome legal proceeding net liability accrue company balance sheet expect material adverse effect company financial position resolution increase accrual matter report period material adverse effect company result operation cash flow period product liability johnson johnson certain subsidiary involve numerous product liability claim lawsuit involve multiple product claimant case seek substantial compensatory available punitive damage company believe substantial defense feasible predict ultimate outcome litigation time time substantial defense company consider isolate settlement base variety circumstance company establish accrual product liability claim lawsuit compliance asc base currently available information case limited company accrue estimate legal defense cost need defend matter cost probable reasonably estimate certain matter company accrue additional amount estimate cost associate settlement damage loss product liability accrual represent project product liability thousand claim world different litigation environment different fact pattern change accrual require future additional information available significant case include depuy asr acetabular system depuy asr hip resurfacing system pinnacle acetabular cup system pelvic mesh risperdal xarelto body powder contain talc primarily johnson baby powder invokana ethicon physiomesh flexible composite mesh december united states approximately plaintiff direct claim pende lawsuit injury allegedly depuy asr acetabular system depuy asr hip resurfacing system respect pinnacle acetabular cup system respect pelvic mesh respect risperdal respect xarelto respect body powder contain talc respect invokanaand respect ethicon physiomesh flexible composite mesh august depuy orthopaedics inc depuy announce worldwide voluntary recall asr acetabular system depuy asr hip resurfacing system hip replacement surgery claim personal injury depuy johnson johnson number pende lawsuit expect fluctuate certain lawsuit settle dismiss additional lawsuit file case file federal court united states organized multi district litigation united states district court northern district ohio litigation file country outside united states primarily united kingdom canada australia ireland germany india italy november depuy reach agreement courtappointe committee lawyer represent asr hip system plaintiff establish program settle claim eligible asr hip patient unite states surgery replacetheir asr hips know revision surgery august depuy reach additional agreement february march extend settlement program include asr hip patient revision surgery august prior february settlement program resolve claim bring resolution significant asr hip litigation activity united states lawsuit united states remain settlement program address litigation outside united states australia class action settlement reach resolve claim majority asr hip patient country canada company reach agreement settle pende class action approve qubec superior court supreme court british columbia company continue receive information respect potential additional cost associate recall worldwide basis company establish accrual cost associate united states settlement program depuy asr hiprelated product liability litigation claim personal injury depuy orthopaedics inc johnson johnson collectively depuy relate pinnacle acetabular cup system hip replacement surgery product liability lawsuit continue file company continue receive information respect potential cost anticipate number case case file federal court united states organize multidistrict litigation united states district court northern district texas litigation file state court country outside united states adverse verdict render depuy reverse appeal remand retrial quarter depuy establish united states settlement program resolve case settlement program adverse verdict settle company establish accrual product liability litigation associated pinnacle acetabular cup system relate settlement program claim personal injury ethicon inc ethicon johnson johnson arising ethicon pelvic mesh device treat stress urinary incontinence pelvic organ prolapse company continue receive information respect potential cost additional case case file federal court united states organize multidistrict litigation mdl united states district court southern district west virginia mdl court remand case trial jurisdiction case originally file additional pelvic mesh lawsuit file remain outside mdl company settle resolve majority united states case estimate cost associate settlement remain case reflect company accrual addition class action individual personal injury case claim commence country outside united states include claim case united kingdom netherlands belgium class action israel australia canada seek damage allege injury result ethicon pelvic mesh device november federal court australia issue judgment finding respect liability relation lead applicant generally relation design manufacture pre postmarket assessment test supply promotion device australia treat stress urinary incontinence pelvic organ prolapse order determine damage amount award lead applicant expect quarter respect group member individual case assessment process require proof use causally relate loss class action canada expect discontinue result settlement group case subject court approval discontinuance company establish accrual respect product liability litigation associate ethicon pelvic mesh product follow june worldwide market withdrawal ethicon physiomesh flexible composite mesh claim personal injury ethicon inc johnson johnson allege personal injury arising use hernia mesh device case file federal court united states organize multidistrict litigation mdl united states district court northern district georgia multicounty litigation mcl form new jersey state court assign atlantic county case pende new jersey addition matter mdl mcl additional lawsuit pende united states district court southern district ohio mdl polypropylene mesh device manufacture bard inc lawsuit pende outside united states ethicon physiomesh lawsuit number filing relate proceed mesh proceed ventral patch product march new jersey supreme court enter order consolidate proceed proceed ventral patch case mcl atlantic county superior court additional case file federal state court jurisdiction outside company continue receive information respect potential cost anticipate number case company establish accrual respect product liability litigation associate ethicon physiomesh flexible composite mesh proceed mesh proceed ventral patch product september plaintiffs attorney file application new jersey supreme court seek centralized management prolene polypropylene hernia system case new jersey supreme court grant plaintiff application january transfer mcl atlantic county superior courtclaim personal injury janssen pharmaceuticals inc johnson johnson arising use risperdal indicate treatment schizophrenia acute manic mixed episode associate bipolar disorder irritability associate autism relate compound lawsuit primarily file state court pennsylvania california missouri action pende court united states canada product liability lawsuit continue file company continue receive information respect potential cost anticipate number case company successfully defend number case verdict company include recent verdict october billion punitive damage relate single plaintiff subsequently reduce january million trial judge company appeal final judgment company settle resolve united states case cost associate settlement reflect company accrual claim personal injury arise use xarelto oral anticoagulant janssen pharmaceuticals inc jpi johnson johnson jpi collaboration partner xarelto bayer certain affiliate case file federal court united states organize multidistrict litigation united states district court eastern district louisiana addition case file state court united states case consolidate state mass tort litigation philadelphia pennsylvania coordinate proceed los angeles california class action lawsuit file canada march jpi announce agreement principle settle xarelto cases united states settlement agreement execute settlement final december resolve majority case pende united states company establish accrual cost associate united states settlement program xarelto relate product liability litigation personal injury claim allege talc cause cancer johnson johnson consumer inc johnson johnson arising use body powder contain talc primarily johnson baby powder number pende product liability lawsuit continue increase company continue receive information respect potential cost anticipate number case lawsuit primarily file state court missouri new jersey california outside united states case file federal court united states organize multidistrict litigation united states district court district new jersey multidistrict litigation party move exclude expert know daubert motion court hold daubert hearing midjuly final round briefing submit court party await decision company successfully defend number case verdict company include verdict july billion company believe strong ground appeal overturn verdict company establish accrual primarily defense cost connection product liability litigation associate body powder contain talc february companys talc supplier imery talc america inc affiliate imery talc vermont inc imerys talc canada inc collectively imery file voluntary chapter petition commence reorganization united states bankruptcy code united states bankruptcy court district delaware imerys bankruptcy imery bankruptcy relate imery potential liability personal injury exposure talcum powder sell imery talc claim bankruptcy filing imery note certain claim allege company indemnification right joint insurance proceed base claim indemnity insurance claim company imery company petitioned united states district court district delaware establish federal jurisdiction state court talc lawsuit bankruptcy code company petition deny state court talc lawsuit remove federal court basis remand company formally propose resolve imery company obligation arise talc claim agree assume defense litigation talc claim involve company product lift automatic stay enable talc claim proceed outside bankruptcy forum company agree settle pay judgment imery waive company indemnification claim imery discussion imery company issue remain ongoing february security class action lawsuit file johnson johnson certain name officer united states district court district new jersey allege johnson johnson violate federal security law failing adequately disclose alleged asbestos contamination body powder contain talc primarily johnson baby powder purchaser johnson johnson share suffer loss result plaintiff seek damage april company move dismiss complaint briefing motion complete august december court deny motion dismiss october shareholder derivative lawsuit file johnson johnson nominal defendant current director defendant united states district court district new jersey allege breach fiduciary dutiesrelate alleged asbestos contamination body powder contain talc primarily johnson baby powder johnson johnson suffer damage result allege breach june shareholder file additional complaint initiate summary proceed new jersey state court book record inspection august johnson johnson respond book record complaint file cross motion dismiss september plaintiff reply court hear oral argument court rule book record action september united states district court district new jersey grant defendant motion dismiss shareholder derivative lawsuit dismiss complaint prejudice october shareholder file notice appeal united states court appeal circuit january shareholder voluntarily dismiss appeal prejudice additional shareholder derivative lawsuit file new jersey make similar allegation company current director certain officer january erisa class action lawsuit file participant johnson johnson savings plan johnson johnson pension benefit committee certain name officer united states district court district new jersey allege defendant breach fiduciary duty offer johnson johnson stock johnson johnson savings plan investment option imprudent failure disclose alleged asbestos contamination body powder contain talc primarily johnson baby powder plaintiff seek damage injunctive relief defendant file motion dismiss lawsuit pende united states district court central district california allege violation proposition california unfair competition law false advertising law concern johnson baby powder june plaintiff file motion voluntary dismissal proposition action company oppose motion extent allow plaintiff counsel refile claim new plaintiff court grant plaintiff motion condition payment attorney fee costs court enter award attorney fee cost october case dismiss prejudice lawsuit allege violation proposition california consumer legal remedy act relate johnson baby powder file superior court california county san diego july company file notice removal united states district court southern district california plaintiff file second amend complaint shortly october company move dismiss second amend complaint failure state claim relief grant primarily basis plaintiff fail comply proposition mandatory presuit notice requirement apply plaintiff assert indirect proposition claim response motion plaintiff file amend complaint december company move dismiss amend complaint failure state claim relief grant addition company receive preliminary inquiry subpoena produce document matter senator murray member senate committee health education labor pensions department justice securities exchange commission congressional subcommittee economic consumer policy company cooperate government inquiry continue produce document response claim personal injury number johnson johnson company include janssen pharmaceuticals inc johnson johnson arising use invokana prescription medication indicate improve glycemic control adult type diabetes lawsuit file federal court united states organize multidistrict litigation united states district court district new jersey case file state court class action lawsuit file canada product liability lawsuit continue file company continue receive information respect potential cost anticipate number case company settled resolve case claim united states cost associate settlement reflect company accrual intellectual property certain subsidiary johnson johnson subject time time legal proceeding claim relate patent trademark intellectual property matter arise business matter involve challenge coverage andor validity patent product allegation certain company product infringe patent party subsidiary believe substantial defense challenge allegation respect significant patent assurance outcome matter loss case adversely affect ability subsidiary sell product result loss sale loss market exclusivity require payment past damage future royalty result noncash impairment charge associate intangible asset significant matter describe belowmedical device march medinol ltd medinol file patent infringement lawsuit cordis corporation cordis johnson johnson united states district court southern district new york allege cordiss sale cypher cypher select stent united states willfully infringe medinol patent direct geometry articulate stent johnson johnson sell cordis retain liability case trial january district court dismiss case find medinol unreasonably delay bring claim lache defense september district court deny motion medinol vacate judgment grant new trial medinol appeal decision united states court appeal federal circuit march united states supreme court hold laches defense available patent case april united states court appeal federal circuit remand case district court reconsider medinol motion new trial march district court deny medinol motion new trial april medinol file notice appeal november medidea llc medidea file patent infringement lawsuit depuy orthopaedics inc united states district court northern district illinois allege infringement attune knee system april medidea file amend complaint add depuy synthes products inc depuy synthes sales inc name defendant collectively depuy medidea allege infringement united states patent nos relate posterior stabilize knee system specifically medidea allege sofcamtm contact feature attune posterior stabilize knee product infringe patentsinsuit medidea seek monetary damage injunctive relief june case transfer united states district court district massachusetts claim construction hearing hold october claim construction order issue november december medidea stipulate noninfringement patent base district court claim construction reserve right appeal construction leave patent issue district court january district court stay case pende decision inter part review proceed patent december depuy synthes products inc file petition inter parte review united states patent trademark office uspto seek invalidate claim patent assert district court litigation june uspto institute review claim hear hold march april uspto issue decision uphold validity patent depuy file motion summary judgment noninfringement claim patent november judgment enter favor depuy december medidea file notice appeal december ethicon endosurgery inc ethicon endosurgery llc know ethicon llc sue covidien inc united states district court district massachusetts seek declaration united states patent nos patent patent invalid infringe ethicon enseal large jaw tissue sealer product april covidien covidien sales llc covidien collectively covidien answer counterclaim deny allegation assert willful infringement patent patent united states patent nos patent patent seek damage injunction covidien file motion preliminary injunction deny october party enter joint stipulation patent patent remain dispute trial begin september closing argument hear march december ford albritton sued acclarent inc acclarent united states district court northern district texas allege acclarent relieva spin relievea spinplus product infringe patent patent albritton allege breach contract fraud true owner acclarent patent december acclarent file petition inter part review ipr united states patent trademark office uspto challenging validity patent uspto institute ipr july july uspto rule favor albritton ipr finding acclarent meet burden proof challenge claim invalid october court appeal affirm usptos patent trial appeal board june party file cross motion summary judgment district court party await decision district court trial schedule april november board regents university texas system tissuegen inc collectively file lawsuit united states district court western district texas ethicon inc ethicon llc allege manufacture sale vicryl plus antibacterial suture monocryl plus antibacterial suture pds plus antibacterial suture stratafix pds antibacterial suture stratafix monocryl plus antibacterial suturesinfringe plaintiffs united states patent nos patent direct implantable polymer drug release biodegradable fiber contain therapeutic agent seek damage injunction december ethicon file petition uspto seek inter parte review ipr assert patent petition stay uspto pending decision supreme court unrelated case dismiss patent suit long accuse pds plus antibacterial suture stratafix pds plus antibacterial sutures infringement district court trial schedule june august intuitive surgical inc intuitive surgical operation inc intuitive file patent infringement suit auris health inc auris united states district court district delaware suit intuitive allege willful infringement patent nos patent patent patent patent patent patent patent patent base auris monarch platform auris file petition inter parte review uspto patent december uspto institute review patent deny review patent district court trial schedule begin january august rsb spine llc rsb spine file patent infringement suit depuy synthes inc united states district court district delaware october rsb spine amend complaint change name defendant depuy synthes sales inc depuy synthes products inc suit rsb spine allege willful infringement united states patent nos follow product zeropva spacer zerop spacer zerop natural plate synfix spacer synfix evolution system rsb spine seek monetary damage injunctive relief november suit consolidated pretrial purpose patent infringement suit bring rsb spine united states district court district delaware life spine inc medacta usa inc precision spine inc xtant medical holdings inc pharmaceutical august sandoz ltd hexal collectively sandoz file lawsuit english high court searle llc pfizer company searle janssen sciences ireland jsi allege searle supplementary protection certificate spcgb spc exclusively license jsi invalid revoke janssencilag limited sell prezista darunavir united kingdom pursuant license october searle jsi counterclaimed sandoz threaten infringement spc base statement plan launch generic darunavir united kingdom sandoz admit generic darunavir product infringe spc find valid searle jsi seek order enjoin sandoz market generic darunavir expiration spc follow trial april court enter decision hold spc valid grant final injunction sandoz appeal court decision injunction stay pende appeal january court refer issue appeal court justice european union cjeu stay proceeding pende cjeus ruling issue december party enter settlement agreement april acerta pharma astrazeneca ltd astrazeneca pharmaceutical file patent infringement lawsuit united states district court district delaware pharmacyclics llc abbvie inc collectively abbvie allege manufacture sale imbruvica infringe patent janssen biotech inc commercialize imbruvica jointly abbvie intervene action november october party enter settlement agreement remicade relate case august celltrion healthcare ltd celltrion inc collectively celltrion file application united states food drug administration fda approval sell infliximab biosimilar march janssen biotech inc jbi file lawsuit united states district court district massachusetts celltrion hospira healthcare corporation hospira exclusive marketing right celltrion infliximab biosimilar united states seek thing declaratory judgment biosimilar product infringe potentially infringe jbi patent include united states patent relate remicade infliximab patent united states patent patent direct cell culture medium celltrion biosimilar august district court grant celltrion hospiras motion summary judgment invalidity patent jbi appeal decision united states court appeal federal circuit january federal circuit dismiss appeal moot base affirmance decision uspto patent trial appeal board affirm invalidity patent june jbi file additional patent infringement lawsuit assert patent celltrion hospira united states district court district massachusetts hyclone laboratories inc manufacturer cell culture medium celltrion use biosimilar product united states district court forthe district utah jbi seek monetary damage relief october district court massachusetts action deny celltrion hospiras motion dismiss lack stand july district court massachusetts action grant celltrion motion summary judgment noninfringement enter order dismiss lawsuit celltrion hospira jbi appeal united states court appeal federal circuit celltrion hospira crossappealed standing issue hear appeal crossappeal schedule march litigation hyclone utah stay pende outcome massachusetts action fda approve infliximab biosimilar sale united states number product launch litigation filer abbreviate new drug application anda follow summarize lawsuit pende generic company file abbreviate new drug application andas fda undertake similar regulatory process outside united states seek market generic form product sell subsidiary johnson johnson prior expiration applicable patent cover product anda typically include allegation noninfringement invalidity applicable patent event subsidiarie successful action automatic statutory stay andas expire united states district court ruling obtain thirdparty company involve ability approval fda introduce generic version product market result potential substantial market share revenue loss applicable product result noncash impairment charge associate intangible asset addition time time subsidiary settle type action settlement involve introduction generic version product issue market prior expiration relevant patent inter part review ipr process united states patent trademark office uspto create america invents act time generic company conjunction anda lawsuit challenge applicable patent zytiga july janssen biotech inc janssen oncology inc janssen research development llc collectively janssen btg international ltd btg initiate patent infringement lawsuit main action united states district court district new jersey number generic company certain affiliate andor supplier file anda seek approval market generic version zytiga expiration united states patent patent generic company include amneal pharmaceutical llc amneal pharmaceutical new york llc collectively amneal apotex inc apotex corp collectively apotex citron pharma llc citron reddys laboratories ltd reddys laboratories inc collectively reddys mylan pharmaceuticals inc mylan inc collectively mylan par pharmaceuticals inc par pharmaceutical companies inc collectively par teva pharmaceuticals usa inc teva wockhardt bio wockhardt usa llc wockhardt ltd collectively wockhardt westward pharmaceutical corp westward hikma pharmaceuticals llc hikma janssen btg initiate patent infringement lawsuit united states district court district new jersey amerigen pharmaceuticals limited amerigen glenmark pharmaceuticals inc glenmark june file anda seek approval market generic version zytiga expiration patent lawsuit consolidate main action august janssen btg file additional jurisdictional protective lawsuit mylan defendant united states district court northern district west virginia stay august janssen btg initiate patent infringement lawsuit united states district court district new jersey teva file anda seek approval market generic version zytiga expiration patent lawsuit consolidated main action december janssen btg enter settlement agreement glenmark february janssen btg file patent infringement lawsuit msn pharmaceuticals inc msn laboratory private limited collectively msn united states district court district new jersey base anda seek approval generic version zytiga prior expiration patent february action stay pende outcome main action april janssen btg enter settlement agreement apotexin october united states district court district new jersey issue ruling invalidating assert claim patent court hold patent claim infringe patent valid janssen appeal court decision november janssen btg initiate patent infringement lawsuit united states district court district new jersey qilu pharmaceutical ltd qilu pharma inc collectively qilu file anda seek approval market generic version zytiga expiration patent janssen seek order enjoin qilu marketing generic version zytiga expiration patent november united states court appeal federal circuit deny janssen request injunction pende appeal result generic version zytiga enter market generic company include amerigen argentum pharmaceuticals llc argentum mylan wockhardt actavis amneal reddys sun teva westward hikma file petition inter parte review ipr uspto seek invalidate patent january uspto issue decision find patent claim unpatentable janssen request rehear december uspto deny janssen request rehear ipr decision janssen file appeal consolidate abovementione appeal decision united states district court district new jersey federal circuit issue decision affirm uspto decision wockhardt ipr patent claim unpatentable dismiss remain appeal moot subsequently janssen dismiss lawsuit msn qilu november janssen initiate notice application section patent medicine notice compliance regulation apotex inc apotex minister health canada response apotexs filing abbreviate new drug submission and seek approval market generic version zytiga expiration canadian patent patent final hearing conclude october court issue order prohibit canadian minister health approve apotexs and expiration patent november apotex file appeal january janssen initiate notice application section patent medicine notice compliance regulation apotex minister health canada response apotexs filing abbreviate new drug submission and seek approval market filmcoate generic version zytiga expiration patent january janssen initiate notice application section patent medicine notice compliance regulations pharmascience inc pharmascience minister health canada response pharmascience file abbreviate new drug submission and seek approval market generic version zytiga expiration patent final hearing schedule begin october november janssen initiate notice application section patent medicine notice compliance regulation pharmascience minister health canada response pharmascience file and seek approval market generic version zytiga expiration patent final hearing schedule begin october january janssen initiate notice application section patent medicine notice compliance regulation sandoz canada inc sandoz minister health canada response sandozs filing abbreviate new drug submission and seek approval market generic version zytiga expiration canadian patent july party enter settlement agreement june janssen initiate notice application section patent medicine notice compliance regulation reddy laboratories ltd reddy laboratory inc collectively drl minister health canada response apotexs filing abbreviate new drug submission and seek approval market generic version zytiga expiration canadian patent final hearing schedule begin october canadian action janssen seek order prohibit minister health issuing notice compliance respect defendant andss expiration janssen patentxarelto begin october janssen pharmaceuticals inc jpi bayer pharma bayer intellectual property gmbh collectively bayer file patent infringement lawsuit united states district court district delaware number generic company file anda seek approval market generic version xarelto expiration bayers united states patent nos relate xarelto jpi exclusive sublicensee assert patent follow generic company name defendant aurobindo pharma limited aurobindo pharma usa inc collectively aurobindo breckenridge pharmaceutical inc breckenridge invagen pharmaceuticals inc invagen micro labs usa inc micro labs ltd collectively micro mylan pharmaceuticals inc mylan prinston pharmaceuticals inc sigmapharm laboratory llc sigmapharm torrent pharmaceutical limited torrent pharma inc collectively torrent trial conclude april july district court enter judgment mylan sigmapharm hold assert compound patent valid infringe september district court enter judgment remain defendant defendant appeal judgment begin april jpi bayer intellectual property gmbh bayer collectively bayer file patent infringement lawsuit united states district court district delaware number generic company file anda seek approval market generic version xarelto expiration bayer ags united states patent relate xarelto jpi exclusive sublicensee asserted patent follow generic company name defendant alembic pharmaceutical limit alembic global hold alembic pharmaceuticals inc alembic aurobindo breckenridge invagen lupin limited lupin pharmaceuticals inc collectively lupin micro mylan sigmapharm taro pharmaceutical industry ltd taro pharmaceuticals usa inc collectively taro torrent lupin counterclaim declaratory judgment noninfringement invalidity united states patent lupin dismiss counterclaim provide covenant sue patent aurobindo taro torrent micro breckenridge invagen sigmapharm lupin alembic agree case stay bind outcome final judgment render defendant case consolidate discovery trial trial begin april closing argument hear june december jpi bayer file patent infringement lawsuit united states district court district delaware teva pharmaceuticals usa inc teva pharmaceutical industries ltd collectively teva file anda seek approval market generic version xarelto expiration bayer ags patent case teva consolidated case purpose teva agree case stay bind outcome final judgment render defendant mylan file petition inter parte review uspto seek invalidate patent december uspto issue decision deny institution mylan petition inter parte review jpi bayer file suit macleod pharmaceuticals ltd macleods pharma usa inc collectively macleod allege infringement patent case macleod consolidated case purpose macleod agree case stay bind outcome final judgment render defendant june jpi bayer file suit accord healthcare inc accord healthcare ltd intas pharmaceuticals ltd collectively accord allege infringement patent august jpi bayer file suit sunshine lake pharma ltd hec pharm usa inc allege infringement patent october jpi bayer enter settlement agreement mylan november jpi bayer enter settlement agreement breckenridge december jpi bayer enter settlement agreement accord micro sigmapharm sunshine torrent january jpi bayer enter settlement agreement macleod consolidated case involve alembic aurobindo invagen lupin taro teva stay march lawsuit jpi seek order enjoin defendant market generic version xareltobefore expiration relevant patent prezista janssen product janssen sciences ireland collectively janssen initiate patent infringement lawsuit united states district court district new jersey reddys laboratories inc reddys laboratories ltd laurus labs ltd pharmaq inc collectively drl file anda seek approval market generic version prezista expiration united states patent nos february party enter settlement agreement december janssen initiate patent infringement lawsuit united states district court district new jersey amneal pharmaceuticals llc amneal pharmaceutical company gmbh amneal pharmaceuticals new york llc amneal pharmaceuticals pvt ltd raks pharma pvt ltd collectively amneal file anda seek approval market generic version prezista expiration united states patent nos april party enter settlement agreement january janssen products janssen sciences ireland unlimited company collectively janssen initiate patent infringement lawsuit united states district court district new jersey zydus pharmaceuticals usa inc cadila healthcare ltd collectively zydus file anda seek approval market generic version prezista expiration united states patent nos janssen seek order enjoin zydus market generic version prezista expiration relevant patent invokanainvokametinvokamet begin july janssen pharmaceuticals inc janssen research development llc cilag gmbh international janssen pharmaceutica collectively janssen mitsubishi tanabe pharma corporation mtpc file patent infringement lawsuit united states district court district new jersey united states district court district colorado united states district court district delaware number generic company file anda seek approval market generic version invokana andor invokamet expiration mtpcs united states patent nos patent andor patent relate invokana invokamet janssen exclusive licensee assert patent follow generic company name defendant apotex inc apotex corp apotex aurobindo pharma usa inc aurobindo macleods pharmaceuticals ltd macleods pharma usa inc invagen pharmaceuticals inc invagen prinston pharmaceuticals inc reddys laboratories inc reddys laboratories ltd hetero usa inc hetero labs limited unitv hetero labs limited msn laboratory private ltd msn pharmaceuticals inc laurus labs ltd indoco remedies ltd zydus pharmaceuticals usa inc zydus sandoz inc sandoz teva pharmaceuticals usa inc lupin ltd lupin pharmaceuticals inc lupin begin july janssen mtpc file patent infringement lawsuit united states district court district new jersey united states district court district colorado sandoz invagen file anda seek approval market generic version invokana andor invokamet expiration mtpcs united states patent patent relate invokana invokamet zydus file anda seek approval market generic version invokana invokamet expiration patent mtpc united states patent relate invokana invokamet mtpcs united states patent relate invokamet patent aurobindo file anda seek approval market generic version invokana expiration patent patent relate invokana janssen exclusive licensee assert patent october colorado lawsuit sandoz dismiss december delaware lawsuit apotex teva dismiss april janssen mtpc file patent infringement lawsuit united states district court district new jersey prinston file anda seek approval market generic version invokana expiration patent relate invokana february janssen mtpc file patent infringement lawsuit united states district court district new jersey lupin file anda seek approval market generic version invokamet expiration patent patent relate invokamet july janssen mtpc file patent infringement lawsuit united states district court district newjersey msn file anda seek approval market generic version invokamet expiration patent patent relate invokamet october janssen mtpc initiate patent infringement lawsuit united states district court district new jersey msn file anda seek approval market generic version invokana invokamet expiration patent october janssen mtpc initiate patent infringement lawsuit united states district court district new jersey drl file anda seek approval market generic version invokamet expiration patent janssen mtpc enter settlement agreement prinston invagen june hetero july apotex teva august trial patent schedule begin april trial patent schedule begin lawsuit janssen mtpc seek order enjoin defendant market generic version invokana invokamet andor invokamet expiration relevant patent opsumit january actelion pharmaceuticals ltd actelion initiate patent infringement lawsuit united states district court district new jersey zydus pharmaceuticals usa inc zydus amneal pharmaceutical llc amneal file anda seek approval market generic version opsumit expiration united states patent patent lawsuit actelion seek order enjoin zydus amneal marketing generic version opsumit expiration patent amneal zydus stipulate infringement february actelion amneal enter settlement agreement trial zydus schedule commence october july actelion pharmaceuticals ltd file suit aurobindo pharma usa inc aurobindo pharma limited aurobindo aurobindo file anda seek approval market generic version opsumit expiration patent actelion seek order enjoin defendant market generic version opsumit expiration patent trial aurobindo schedule commence july invega sustenna january janssen pharmaceutica janssen pharmaceuticals inc collectively janssen initiate patent infringement lawsuit united states district court district new jersey teva pharmaceuticals usa inc teva file anda seek approval market generic version invega sustenna expiration united states patent trial schedule begin june august janssen pharmaceutica janssen pharmaceuticals inc collectively janssen initiate patent infringement lawsuit united states district court district new jersey mylan laboratories limited mylan file anda seek approval market generic version invega sustenna expiration patent december janssen pharmaceutica janssen pharmaceuticals inc collectively janssen initiate patent infringement lawsuit united states district court district new jersey delaware pharmascience inc mallincrodt plc specgx llc collectively pharmascience file anda seek approval market generic version invega sustenna expiration united states patent february janssen inc janssen pharmaceutica collectively janssen initiate notice application section patent medicine notice compliance regulation teva canada limited teva minister health response teva filing abbreviate new drug submission and seek approval market generic version invega sustenna expiration canadian patent nos janssen seek order prohibit minister health issuing notice compliance respect tevas and expiration patent final hearing schedule begin february lawsuit janssen seek order enjoin defendant marketing generic version invega sustenna expiration patentimbruvica begin january pharmacyclic llc pharmacyclic janssen biotech inc jbi file patent infringement lawsuit united states district court district delaware number generic company file anda seek approval market generic version imbruvica capsulesbefore expiration pharmacyclic united states patent nos andor relate imbruvica jbi exclusive licensee assert patent follow generic company name defendant cipla limited cipla usa inc cipla fresenius kabi usa llc fresenius kabi usa inc fresenius kabi oncology limit fresenius kabi sandoz inc lek pharmaceutical sandoz shilpa medicare limited shilpa sun pharma global fze sun pharmaceutical industry limited sun teva pharmaceuticals usa inc teva zydus worldwide dmcc cadila healthcare limited zydus trial schedule begin october october pharmacyclic jbi file patent infringement lawsuit united states district court district delaware sun assert united states patent november pharmacyclic jbi file patent infringement lawsuit united states district court district delaware hetero labs limited hetero labs limited unit hetero labs limited unitv hetero usa inc hetero file anda seek approval market generic version imbruvica capsules assert infringement united states patent nos january pharmacyclic jbi amend complaint fresenius kabi zydus teva sandoz allege infringement patent nos january pharmacyclic jbi file patent infringement lawsuit united states district court district delaware zydus file anda seek approval market generic version imbruvica expiration patent nos january pharmacyclic jbi file patent infringement lawsuit united states district court district delaware hetero asserting infringement united states patent february pharmacyclic jbi amend complaint cipla shilpa sun allege infringement united states patent nos february pharmacyclic jbi enter settlement agreement teva hetero march pharmacyclics jbi enter settlement agreement shilpa march pharmacyclic jbi file patent infringement lawsuit united states district court district delaware alvogen pine brook llc natco pharma ltd alvogen file anda seek approval market generic version imbruvica tablet assert infringement united states patent nos pharmacyclic jbi amend complaint cipla allege infringement united states patent june pharmacyclic jbi amend complaint alvogen allege infringement united states patent august pharmacyclic jbi amend complaint cipla fresenius sandoz allege infringement patent nos amend complaint sun allege infringement patent march sandoz file inter parte review ipr uspto seek invalidate united states patent lawsuit pharmacyclic jbi seek order enjoin defendant market generic version imbruvica expiration relevant patentstracleer actelion pharmaceuticals ltd actelion pharmaceutical inc initiate patent infringement lawsuit united states district court district new jersey natco pharma limited syneos health llc collectively natco file anda seek approval market generic version tracleer expiration patent patent lawsuit actelion seek order enjoin natco marketing generic version tracleer expiration patent november party enter settlement agreement december actelion pharmaceuticals ltd actelion pharmaceutical inc initiate patent infringement lawsuit united states district court district new jersey zydus pharmaceuticals usa inc cadila healthcare limit collectively zydus file anda seek approval market generic version tracleer expiration patent patent actelion seek order enjoin zydus market generic version tracleer expiration patent risperdal consta july janssen pharmaceuticals inc alkerme pharma ireland limited alkerme control therapeutics inc initiate patent infringement lawsuit united states district court district delaware luye pharma group ltd luye pharma usa ltd nanjing luye pharmaceutical ltd shandong luye pharmaceutical ltd collectively luye file anda seek approval market generic version risperdal consta expiration united states patent november party enter settlement lawsuit janssen seek order enjoin luye market generic version risperdal consta expiration patent government proceeding like company pharmaceutical consumer medical device industry johnson johnson certain subsidiary subject extensive regulation national state local government agency united states country operate result interaction government agency ongoing significant litigation bring investigation conduct government agency list possible criminal charge substantial fine andor civil penalty damage result government investigation litigation average wholesale price awp litigation johnson johnson pharmaceutical subsidiary awp defendant numerous pharmaceutical company name defendant series lawsuit state federal court involve allegation pricing market certain pharmaceutical product amount fraudulent actionable conduct thing company allegedly report inflated average wholesale price awp drug issue payor allege awps calculate provider reimbursement level plaintiff case include class private person entity pay portion purchase drug issue base awp state government entity medicaid payment drug issue base awp case federal action state action remove federal court consolidated pretrial purpose multidistrict litigation united states district court district massachusetts claim awp defendant ultimately dismiss awp defendant prevail case bring commonwealth pennsylvania awp case resolve court order settlement case bring illinois settle trial new jersey putative class action base awp allegation pende centocor inc ortho biotech inc janssen biotech inc johnson johnson alza corporation case resolve opioid litigation begin continue present johnson johnson janssen pharmaceuticals inc jpi pharmaceutical company name lawsuit bring certain state local government relate marketing opioid include duragesic nucynta nucynta suit raise allegation relate previously own active pharmaceutical ingredient supplier subsidiary tasmanian alkaloid pty ltd noramco inc subsidiary divest similar lawsuit file follow group plaintiff individual plaintiff behalf child suffer neonatal abstinence syndrome hospital health insurerspayorsto date complaint pharmaceutical company include johnson johnson jpi file state attorney general arkansas florida idaho illinois kentucky louisiana mississippi missouri new hampshire new jersey new mexico new york ohio oklahoma south dakota texas washington west virginia complaint manufacturer file state federal court city county local government agency follow states alabama arkansas california connecticut florida georgia illinois kentucky louisiana maine maryland massachusetts mississippi missouri nevada new hampshire new jersey new mexico new york north carolina ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah virginia washington west virginia wisconsin government puerto rico file suit superior court san juan case pende state court federal case coordinate federal multidistrict litigation mdl pende district court northern district ohio mdl addition province british columbia file suit canada october antitrust complaint file private plaintiff federal court tennessee pende transfer mdl action allege variety claim relate opioid marketing practice include false advertising unfair competition public nuisance consumer fraud violation deceptive act practice false claim unjust enrichment suit generally seek penalty andor injunctive monetary relief suit plaintiff seek joint liability defendant adverse judgment lawsuit result imposition large monetary penalty significant damage include punitive damage cost abatement substantial fine equitable remedy sanction trial matter file oklahoma attorney general result judgment johnson johnson jpi million subject final order issue court court issue final judgment reduce million johnson johnson jpi appeal judgment company believe strong ground overturn judgment october johnson johnson jpi announce settlement case set trial mdl county ohio johnson johnson jpi pharmaceutical company receive subpoena request information relate opioids marketing practice follow state attorney general alaska indiana montana new hampshire south carolina tennessee texas washington september johnson johnson jpi contacted texas colorado attorney general office behalf approximately state multistate attorney general investigation october company announce propose agreement principle include company pay billion settlement lawsuit subject condition agreement finalize agreement principle admission liability wrongdoing resolve opioid lawsuit file future claim state city county company predict agreement finalize individual case ongoing include trial new york schedule commence march august johnson johnson receive grand jury subpoena united states attorney office eastern district new york document relate company antidiversion policy procedure distribution opioid medication company understand broad investigation manufacturer distributor monitor program report control substance act september johnson johnson receive subpoenas new york state department financial service nydfs industrywide inquiry effect opioid prescription new york health insurance premium company cooperate produce document response subpoena request information august depuy orthopaedics inc depuy inc know depuy synthes inc johnson johnson services inc collectively depuy receive informal request united states attorney office district massachusetts civil division united states department justice united states production material relate depuy asr hip device july united states notify united states district court district massachusetts decline intervene qui tam case file pursuant false claim act company february district court grant company motion dismiss prejudice unseal qui tam complaint deny qui tam relator request leave file amend complaint qui tam relator appeal case united states court appeal circuit july circuit affirm district court dismissal reverse affirm decision deny relator request file amend complaint relator remain claim pende district court fact discovery currently schedule close march october johnson johnson contact california attorney general office multistate attorney general investigation market surgical mesh product hernia urogynecological purpose johnson johnson subsidiary ethicon inc ethicon california washington file civil complaint johnson johnson ethicon ethicon llc allege violation consumer protection statute april johnson johnson ethicon settle washington case california case start trial july conclude september january court find favor state award state civil penalty approximately million company intend appeal proceeding conclude trial court similar complaint file company kentucky august mississippi october west virginia september oregon december trial date kentucky case schedule september adjourn new trial date schedule october johnson johnson ethicon settle multistate investigation state district columbia december therakos inc therakos subsidiary johnson johnson orthoclinical diagnostics inc ocd franchise receive letter civil division united states attorney office eastern district pennsylvania inform therakos united states attorney office investigate sale marketing uvadex methoxsalen uvar xts cellex systems period present united states attorney office request ocd johnson johnson preserve document relate investigation therakos subsequently acquire affiliate gore capital partner iii january ocd divest june follow divestiture ocd johnson johnson retain ocds portion liability result investigation activity occur prior sale therakos march march united states attorney office request johnson johnson produce certain document johnson johnson cooperate request june mississippi attorney general file complaint chancery court judicial district hind county mississippi johnson johnson johnson johnson consumer companies inc know johnson johnson consumer inc jjci complaint allege defendant violate mississippi consumer protection act fail disclose allege health risk associate female consumer use talc contain johnson baby powder johnson shower shower product divest seek injunctive monetary relief matter stay pende interlocutory appeal december denial johnson johnson jjci motion summary judgment mississippi supreme court grant jjci request file interlocutory appeal denial motion summary judgment late soon establish briefing schedule company receive inquiry state attorney general march janssen pharmaceuticals inc jpi receive civil investigative demand united states attorney office southern district new york relate jpis contractual relationship pharmacy benefit manager period january present regard certain jpi pharmaceutical product demand issue connection investigation false claim act july johnson johnson janssen products serve qui tam complaint pursuant false claim act file united states district court district new jersey allege offlabel promotion hiv product prezista intelence antikickback violation connection promotion product complaint file seal december federal state government decline intervene lawsuit prosecute relator january janssen pharmaceuticals inc jpi receive civil investigative demand united states department justice relate allegation concern sale marketing practice olysio december johnson johnson jpi serve whistleblow lawsuit file united states district court central district california allege offlabel promotion olysio additional product include nucynta xarelto levaquin remicade time federal state government decline intervene lawsuit relate civil investigative demand prosecute company employee united states district court central district california dismiss claim april relator file notice appeal united states court appeals ninth circuit january court appeal ninth circuit dismiss relator appeal november second whistleblow lawsuit unseal united states district court central district california lawsuit substantially similar lawsuit appeal bring original relator federal state government decline intervene second suit relator move dismiss lawsuit prejudice april court grant relator motion dismiss complaint prejudice march janssen biotech inc receive civil investigative demand united states department justice false claim act investigation concern management advisory service provide rheumatology gastroenterology practice purchase remicade simponi aria august unite states department ofjustice notify janssen biotech inc closing investigation january janssen biotech inc serve newlyunseale qui tam suit file district court district massachusetts april september johnson johnson receive subpoenas united states attorney district massachusetts seek document broadly relate pharmaceutical copayment support program darzalex olysio remicade simponi stelara zytiga subpoena seek document relate average manufacturer price good price reporting center medicare medicaid services relate product rebate payment state medicaid agencies june johnson johnson receive subpoena united states attorney office district massachusett seek information practice pertain sterilization depuy synthes inc spinal implant hospital boston interaction employee company subsidiary physicians hospitals johnson johnson depuy synthes inc produce document response subpoena fully cooperate government investigation july public prosecution service rio janeiro representatives brazilian antitrust authority cade inspect office company include johnson johnson brasil indstria comrcio produtos para sade ltda authority appear investigate allegation possible anticompetitive behavior possible improper payment medical device industry united states department justice united states securities exchange commission additional inquiry johnson johnson brasil indstria comrcio produtos para sade ltda cooperating request january new mexico attorney general office file suit johnson johnson johnson johnson consumer company inc judicial district court new mexico suit relate safety marketing company talc product state include claim violation new mexico unfair practice act medicaid fraud act fraud taxpayer act fraud negligent misrepresentation negligence unjust enrichment state attorney general inform company conduct inquiry matter time time company receive request variety united states congressional committee produce information relevant ongoing congressional inquiry policy johnson johnson cooperate inquiry produce request information general litigation purport class action file federal court united states district court central district california united states district court southern district illinois johnson johnson johnson johnson consumer companies inc know johnson johnson consumer inc jjci allege violation state consumer fraud statute base nondisclosure allege health risk associate talc contain johnson baby powder johnson shower shower product long sell jjci case seek injunctive relief monetary damage include claim personal injury october case transfer united states district court district court new jersey newly create federal multi district litigation july district court grant johnson johnson jjcis motion dismiss case september united states court appeal circuit affirm dismissal september plaintiff second case voluntarily dismiss complaint march plaintiff second case refile illinois state court august united states customs border protection cbp issue penalty notice janssen ortho llc janssen ortho assess penalty allege improper classification darunavir ethanolate active pharmaceutical ingredient prezista connection importation united states october janssen ortho submit petition relief response penalty notice cbp issue amend penalty notice assess substantial penalty janssen ortho file petition relief july cbp issue mitigation decision determine janssen ortho negligently misrepresent darunavir ethanolate entitle duty free treatment june janssen ortho file supplemental petition relief penalty proceed impact related classification litigation pende united states court international trade classification litigation determine darunavir ethanolate properly classify exempt duty importation united states trial classification litigation hold july february court rule darunavir ethanolate eligible duty free treatment march april putative class action complaint file contact lens patient number courtsaround united states johnson johnson vision care inc jjvci contact lens manufacturer distributor retailer allege vertical horizontal conspiracy fix retail price contact lense complaint allege manufacturer reach agreement certain distributor retailer concern price contact lense sold consumer plaintiff seek damage injunctive relief class action case transfer united states district court middle district florida june plaintiff file consolidated class action complaint november december district court grant plaintiff motion class certification defendant file motion interlocutory appeal class certification united states court appeal eleventh circuit motion deny defendant motion summary judgment deny november trial schedule june august thirdparty payor file purport class action united states district court eastern district louisiana janssen research development llc janssen ortho llc janssen pharmaceuticals inc orthomcneil janssen pharmaceuticals inc johnson johnson certain bayer entity allege defendant improperly market promote xarelto safe effective expensive alternative medication fail fully disclose risk complaint seek damage september pfizer inc pfizer file antitrust complaint johnson johnson janssen biotech inc collectively janssen united states district court eastern district pennsylvania pfizer allege janssen violate federal antitrust law contract strategy remicade complaint seek damage injunctive relief discovery ongoing begin september multiple purport class action direct indirect purchaser file johnson johnson janssen biotech inc collectively janssen allege janssens remicade contracting strategy violate federal state antitrust consumer law seek damage injunctive relief november case consolidated pretrial purpose united states district court eastern district pennsylvania remicade antitrust litigation motion dismiss deny direct indirect purchaser case motion compel arbitration direct purchaser case deny district court united states court appeal circuit reverse district court ruling june walgreen kroger file antitrust complaint johnson johnson janssen biotech inc collectively janssen united states district court eastern district pennsylvania complaint allege janssen violate federal antitrust law contract strategy remicade complaint seek damage injunctive relief march summary judgment grant favor janssen ruling appeal united states court appeal circuit june united states federal trade commission ftc issue civil investigative demand johnson johnson connection investigation janssen remicade contracting practice violate federal antitrust law company produce document information responsive civil investigative demand october certain united states service member family bring complaint number pharmaceutical medical device company include johnson johnson certain subsidiary allege defendant violate united states antiterrorism act complaint allege defendant provide fund terrorist organization sale practice pursuant pharmaceutical medical device contract iraqi ministry health january plaintiff motion file second amend complaint add plaintiff lawsuit grant april company move dismiss second amend complaint october separate putative class action file actelion pharmaceutical ltd actelion pharmaceutical inc actelion clinical research inc collectively actelion united states district court district maryland united states district court district columbia complaints allege actelion violate state federal antitrust unfair competition law allegedly refuse supply generic pharmaceutical manufacturer sample tracleer tracleer subject risk evaluation mitigation strategy impose restriction distribution product january plaintiff dismiss district columbia case file consolidated complaint united states district court district maryland october court grant actelion motion dismiss amend complaint plaintiff appeal decision december janssen biotech inc janssen oncology inc janssen research development llc johnson johnson collectively janssen serve qui tam complaint file behalf united states states district columbia complaint file december united states district court northern district california allege janssen violate federal false claim act state law provide pricinginformation zytiga government connection direct government sale governmentfunde drug reimbursement program time federal state government decline intervene case transfer united states district court district new jersey janssen move dismiss complaint april blue cross blue shield louisiana hmo louisiana inc file class action complaint janssen biotech inc janssen oncology inc janssen research development llc btg international limited united states district court eastern district virginia additional complaint file complaint generally allege defendant violate antitrust consumer protection law state sherman act pursue patent litigation relate zytigain order delay generic entry case transfer united states district court district new jersey consolidated pretrial purpose class action antitrust complaint file janssen ireland janssen johnson johnson complaint allege janssen violate federal state antitrust consumer protection law agree exclusivity provision agreement gilead concern development marketing combination antiretroviral therapy cart treat hiv complaint allege gilead enter similar agreement bristolmyerssquibb japan tobacco case pende united states district court district northern california defendant file motion dismiss complaint october innovative health llc file complaint biosense webster inc bwi united statesdistrict court middle district california complaint allege certain bwis business practice contractual term violate antitrust law united states state california restricting competition sale high density mapping catheter ultrasound catheter bwi file motion dismiss complaint company receive notice pfizer inc sanofi consumer health inc november boehringer ingelheim pharmaceuticals inc january tender defense indemnification legal claim relate personal injury matter putative class action canada relate zantac ranitidine product notice base certain indemnification provision assume liability connection stock asset purchase agreement pfizer inc company plaintiff underlie suit allege generally zantac overthe counter ranitidine medication contain unsafe level ndma nnitrosodimethylamine cause andor cause cancer patient product plaintiff seek injunctive monetary relief johnson johnson subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund comparable state local foreign law primary relief seek cost past andor future remediation restructure company announce plan implement series action global supply chain intend focus resource increase investment critical capability technology solution necessary manufacture supply product portfolio enhance agility drive growth global supply chain action include expand use strategic collaboration bolster initiative reduce complexity improve costcompetitiveness enhance capability optimize supply chain network additional detail global supply chain restructure strategic collaboration note consolidated financial statement company record pretax charge billion include follow line consolidate statement earning billion restructuring billion income expense billion cost product sell total project cost approximately billion record restructure announce follow table additional detail restructure program total company expect global supply chain action generate approximately billion billion annual pretax cost saving substantially deliver company expect record pretax restructuring charge approximately billion billion year period activity cost associate network optimization exit cost accelerate depreciation amortization follow table summarize severance charge associate spending initiative fiscal year end severance asset writeoff total dollar millions reserve balance december activity reserve balance december current year activity charge cash payment settle non cash reserve balance december cash outlay severance expect substantially pay year accordance company plan local law include project expense salary employee support initiative consulting expense relate pension relate actuarial loss associate transfer employee jabil inc strategic collaboration company continuously reevaluate severance reserve relate restructuring timing payment plan release associate longerterm project company believe exist severance reserve sufficient cover global supply chain plan give period action place company continue assess adjustment necessary additional amount probable estimable report independent register public accounting firm board director shareholders johnson johnson opinions financial statement internal control financial reporting audit accompany consolidated balance sheet johnson johnson subsidiaries company december december relate consolidated statement earning comprehensive income equity cash flow fiscal year period end december include related note collectively refer consolidated financial statement audit company internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso opinion consolidated financial statement refer present fairly material respect financial position company december december result operation cash flow fiscal year period end december conformity accounting principle generally accept united states america opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue coso basis opinion company management responsible consolidated financial statement maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company consolidate financial statement company internal control financial reporting base audits public accounting firm register public company accounting oversight board united states pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audits obtain reasonable assurance consolidated financial statement free material misstatement error fraud effective internal control financial reporting maintain material respect audits consolidated financial statement include perform procedure assess risk material misstatement consolidated financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure consolidated financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation consolidate financial statement audit internal control financial reporting include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk audits include perform procedure consider necessary circumstance believe audits provide reasonable basis opinion describe management report internal control financial reporting management exclude ciz holding ltd cilabo assessment internal control financial reporting december acquire company business combination exclude cilabo audit internal control financial reporting cilabo whollyowne subsidiary total asset exclude intangible asset goodwill total sale exclude management assessment audit internal control financial reporting represent relate consolidated financial statement amount fiscal year end december definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance thereliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate critical audit matter critical audit matter communicate matter arise current period audit consolidated financial statement communicate require communicate audit committee relate account disclosure material consolidated financial statement involve especially challenge subjective complex judgment communication critical audit matter alter way opinion consolidated financial statement take communicate critical audit matter provide separate opinion critical audit matter account disclosure relate pharmaceutical rebate reserve manage care medicare medicaid describe note consolidated financial statement company recognize revenue product sale obligation term contract customer satisfy rebate discount provide customer account variable consideration record reduction sale liability rebate discount recognize accrue rebate return promotion consolidate balance sheet significant portion liability relate rebate sale pharmaceutical good primarily manage care medicare medicaid program amount billion december significant rebate program include manage care medicare medicaid rebate program rebate discount estimate management base contractual term historical experience patient outcome trend analysis project market condition pharmaceutical market principal consideration determination perform procedure relate pharmaceutical rebate reserve manage care medicare medicaid critical audit matter use significant judgment management significant measurement uncertainty involve develop reserve turn lead high degree auditor judgment subjectivity audit effort apply procedure assumption relate contractual term customer historical experience patient outcome trend analysis project market condition address matter involve perform procedure evaluate audit evidence connection form overall opinion consolidated financial statement procedure include testing effectiveness control relate pharmaceutical rebate reserve manage care medicare medicaid include control assumption estimate rebate procedure include develop independent estimate rebate utilize party information price market condition term specific rebate program historical trend actual rebate claim pay testing rebate claim process company include evaluate claim consistency contractual mandate term company rebate arrangement iii compare independent estimate management estimate litigation contingency talc describe note consolidated financial statement company record accrual loss contingency associate legal matter include talc probable liability incur loss reasonably estimate extent adverse verdict render company management record accrual loss determine probable reasonably estimate matter management unable estimate reasonably possible loss range loss ability estimate judgment affect factor include thing damage seek proceeding unsubstantiated indeterminate scientific legal discovery commence complete proceeding early stage matter present legal uncertainty significant fact dispute procedural jurisdictional issue uncertainty unpredictability thenumber potential claim numerous party involve verdict company matter include verdict july billion describe management company believe strong ground appeal overturn verdict company establish accrual primarily defense costsin connection product liability litigation associate body powder contain talc principal consideration determination perform procedure relate talc litigation critical audit matter use significant judgment management assess likelihood loss incur management determination reasonable estimate loss range loss claim turn lead high degree auditor judgment effort evaluate management assessment loss contingency associate litigation address matter involve perform procedure evaluate audit evidence connection form overall opinion consolidated financial statement procedure include testing effectiveness control relate management evaluation talc litigation include control determine loss probable loss reasonably estimate financial statement disclosure procedure include gain understanding company process accounting report talc litigation discuss status significant know actual potential litigation company inhouse legal counsel external counsel deem necessary iii obtain evaluate letter audit inquiry internal external legal counsel significant litigation evaluate reasonableness management assessment unfavorable outcome reasonably possible probable reasonably estimable evaluate sufficiency company litigation contingency disclosure litigation opioid describe note consolidated financial statement company record accrual loss contingency associate legal matter include opioid probable liability incur loss reasonably estimate extent adverse verdict render company management record accrual loss determine probable reasonably estimate matter management unable estimate reasonably possible loss range loss amount accrue legal contingency result complex series judgment future event uncertainty rely heavily estimate assumption include time relate payment ability estimate judgment affect factor include thing damage seek proceeding unsubstantiated indeterminate matter present legal uncertainty significant fact dispute procedural jurisdictional issue uncertainty unpredictability number potential claim numerous party involve company name numerous lawsuit bring certain state local government relate opioid matter trial matter file oklahoma attorney general result judgment company million subsequently reduce million company appeal judgment describe management believe strong ground overturn judgment separately october company announce propose agreement principle include company pay billion settlement lawsuit subject condition agreement finalize company predict agreement finalize company record pretax charge billion fiscal year end december matter principal consideration determination perform procedure relate opioid litigation critical audit matter use significant judgment management assess likelihood loss incur judgment company oklahoma management determination reasonable estimate range loss propose agreement principle settle opioids litigation turn lead high degree auditor judgment effort evaluate management assessment loss contingency associate litigation address matter involve perform procedure evaluate audit evidence connection form overall opinion consolidated financial statement procedure include testing effectiveness control relate management evaluation opioid litigation include control determine loss probable loss reasonably estimate financial statement disclosure procedure include gain understanding company process accounting reporting opioid litigation discuss status significant know actual potential litigation ongoing settlement negotiation company inhouse legal counsel external counsel deem necessary iii obtain evaluate letter audit inquiry internal external legal counsel significant litigation evaluate reasonableness management assessment unfavorable outcome reasonably possible probable reasonably estimable evaluate sufficiency company litigation contingency disclosuress pricewaterhousecooper llp florham park new jersey february serve company auditor able determine specific year begin serve auditor company management report internal control financial reporting section sarbanesoxley act management require assess effectiveness company internal control financial reporting end fiscal year report base assessment company internal control financial report effective management company responsible establish maintain adequate internal control financial reporting company internal control financial reporting design provide reasonable assurance reliability company financial reporting preparation external financial statement accordance generally accept accounting principle internal control financial reporting matter design inherent limitation internal control financial reporting determine effective provide reasonable assurance respect financial statement preparation prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate company management assess effectiveness company internal control financial reporting december make assessment company criterion establish committee sponsor organization treadway commission coso internal controlintegrate framework criterion area control environment risk assessment control activity information communication monitoring company assessment include extensive documenting evaluating testing design operating effectiveness internal control financial reporting company acquire ciz holding ltd cilabo business combination january cilabo total asset exclude intangible asset goodwill total sale represent related consolidated financial statement amount fiscal year end december acquisition occur fiscal year scope company assessment design effectiveness internal control financial reporting fiscal year exclude mention acquisition exclusion accordance sec general guidance assessment recently acquire business omit scope year acquisition base company process assessment describe management conclude december company internal control financial report effective effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear alex gorsky joseph wolk alex gorsky joseph wolk chairman board director executive vice president chief financial officer chief executive officer shareholder return performance graph set forth line graph compare cumulative total shareholder return company common stock period year year end december cumulative total return standard poor stock index standard poors pharmaceutical index standard poors health care equipment index graph table assume invest december december company common stock standard poor stock index standard poors pharmaceutical index standard poors health care equipment index dividend reinveste year shareholder return performance indices johnson johnson index pharmaceutical index healthcare equipment index year shareholder return performance indices johnson johnson index pharmaceutical index healthcare equipment index item change disagreement accountant account financial disclosure applicable item control procedure disclosure control procedure end period cover report company evaluate effectiveness design operation disclosure control procedure company disclosure control procedure design ensure information require disclose company report file submit exchange act record process summarize report time period specify sec rule form disclosure control procedure include limitation control procedure design ensure information require disclose company report file submit exchange act accumulate communicate company management include principal executive principal financial officer person perform similar function appropriate allow timely decision require disclosure alex gorsky chairman chief executive officer joseph wolk executive vice president chief financial officer review participate evaluation base evaluation messr gorsky wolk conclude end period cover report company disclosure control procedure effective report internal control financial reporting information call item incorporate reference management report internal control financial reporting attestation internal control financial reporting include report independent register public accounting firm include item report change internal control financial reporting fiscal quarter end december change companys internal control financial reporting identify connection evaluation require rules exchange act materially affect reasonably likely materially affect company internal control financial reporting company implement multiyear enterprisewide initiative integrate simplify standardize process system human resource information technology procurement supply chain finance function enhancement support growth company financial share service capability standardize financial system initiative response identify deficiency weakness company internal control financial reporting response initiative company continue align streamline design operation financial control environment item information applicable iii item director executive officer corporate governance information call item incorporate reference discussion audit committee caption item election director board committee material caption item election director stock ownership section compliance delinquent section report proxy statement material caption executive officer registrant report company code business conduct cover employee include chief executive officer chief financial officer controller meet requirement sec rules promulgate section sarbanesoxley act code business conduct available company website wwwjnjcomcode ofbusinessconduct copy available shareholder charge write request secretary company principal executive office substantive amendment code business conduct waiver code grant chief executive officer chief financial officer controller post company website wwwinvestorjnjcomgovcfm business day retain website year addition company adopt code business conduct ethic member board director executive officer code business conduct ethic member board director executive officer available company website wwwinvestorjnjcomgovboardconductcfm copy available shareholder charge write request secretary company principal executive office substantive amendmentto code waiver code grant member board director executive officer post company website wwwinvestorjnjcomgovcfm business day retain website year item executive compensation information call item incorporate reference material caption item election director director compensation item compensation committee report compensation discussion analysis executive compensation table proxy statement material incorporate reference material caption compensation committee report proxy statement shall deem furnish file report shall deem incorporate reference filing security act amend securities exchange act amend result furnish extent company specifically incorporate reference item security ownership certain beneficial owner management relate stockholder matter information call item incorporate reference material caption item stock ownership section compliance proxy statement note common stock stock option plan stock compensation agreement note consolidated financial statement item report equity compensation plan information follow table provide certain information december concern share company common stock issue exist equity compensation plan number security weighted issue average exercise exercise price number security outstanding outstanding remain available option option future issuance equity plan category right right compensation plan equity compensation plan approve security holder equity compensation plan approve security holder total include category follow equity compensation plan approve company shareholder longterm incentive plan longterm incentive plan column exclude share reflect column number security issue exercise outstanding option right longterm incentive plan expire april option restrict share grant subsequent date longterm incentive plan item certain relationship relate transaction director independence information call item incorporate reference material caption item election director director independence relate person transaction proxy statement item principal accountant fee service information call item incorporate reference material caption item ratification appointment independent register public accounting firm proxy statement item exhibit financial statement schedule follow document file report financial statement consolidate balance sheet end fiscal year consolidated statement earning fiscal year consolidate statement comprehensive income fiscal year consolidated statement equity fiscal year consolidated statement cash flow fiscal year note consolidated financial statement report independent register public accounting firm schedule omit applicable require information include financial statement note exhibit require file item regulation information call item incorporate reference exhibit index report item summary registrant voluntarily include summary information require item company elect include summary information signature pursuant requirement section securities exchange act registrant duly cause report sign behalf undersigned thereunto duly authorize date february johnson johnson registrant gorsky gorsky chairman board director chief executive officer pursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate signature title date gorsky chairman board director february gorsky chief executive officer principal executive officer chief financial officer wolk february wolk principal financial officer controller chief accounting officer decker february decker principal accounting officer director beckerle february beckerle director davis february davis director davis february davis director doudna february doudna signature title date hewson director february hewson joly director february joly mcclellan director february mcclellan director mulcahy february mulcahy director perez february perez director prince february prince director washington february washington director weinberger february weinberger director williams february williams exhibit index reg exhibit table description item exhibit restate certificate incorporation effective february incorporate reference exhibit registrant annual report fiscal year end january bylaw company amend effective january incorporate reference exhibit registrant form current report file january request security exchange commission registrant furnish copy instrument define right holder longterm debt registrant longterm incentive plan incorporate reference exhibit registrant registration statement file commission file form stock option certificate longterm incentive plan incorporate reference exhibit registrant form current report file january longterm incentive plan incorporate reference appendix registrant proxy statement file commission march form stock option certificate restrict share unit certificate performance share unit certificate longterm incentive plan incorporate reference